

Role of the histone deacetylase complex in acute promy

Nature

391, 811-814

DOI: 10.1038/35895

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Role of RAR α and Its Fusion Partners in Acute Promyelocytic Leukemia. , 0, , 325-378.		0
2	Acute myeloid leukemia and related precursor neoplasms. , 2011, , 272-309.		2
3	Fear conditioning induces associative long-term potentiation in the amygdala. Nature, 1997, 390, 604-607.	13.7	1,247
4	The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1. Nature, 1997, 389, 974-978.	13.7	246
5	The thyroid hormone receptor functions as a ligand-operated developmental switch between proliferation and differentiation of erythroid progenitors. EMBO Journal, 1998, 17, 4291-4303.	3.5	81
6	Cloning and characterization of mCtBP2, a co-repressor that associates with basic Kruppel-like factor and other mammalian transcriptional regulators. EMBO Journal, 1998, 17, 5129-5140.	3.5	301
7	Leukemic transformation by the v-ErbA oncoprotein entails constitutive binding to and repression of an erythroid enhancer invivo. EMBO Journal, 1998, 17, 7382-7394.	3.5	30
8	Life, death and nuclear spots. Nature Genetics, 1998, 20, 220-222.	9.4	18
9	PML induces a novel caspase-independent death process. Nature Genetics, 1998, 20, 259-265.	9.4	357
10	Pml is essential for multiple apoptotic pathways. Nature Genetics, 1998, 20, 266-272.	9.4	507
11	Fusion proteins of the retinoic acid receptor- α recruit histone deacetylase in promyelocytic leukaemia. Nature, 1998, 391, 815-818.	13.7	1,015
14	Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature, 1998, 394, 203-206.	13.7	1,396
16	Targeting the PML/RAR α translocation product triggers apoptosis in promyelocytic leukemia cells. Oncogene, 1998, 17, 1759-1768.	2.6	51
17	Secondary leukemias induced by topoisomerase-targeted drugs. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1998, 1400, 233-255.	2.4	353
18	The carboxy-terminal end of the candidate tumor suppressor gene HIC-1 is phylogenetically conserved. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1998, 1443, 230-232.	2.4	14
19	The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Cancer, 1998, 83, 1471-1482.	2.0	137
20	Role of histone deacetylases in acute leukemia. , 1998, 72, 194-202.		54
21	Regulation and regulatory parameters of histone modifications. , 1998, 72, 203-213.		87

#	ARTICLE	IF	CITATIONS
22	Translocations, fusion genes, and acute leukemia. , 1998, 72, 264-276.		17
23	Co-activators and co-repressors in the integration of transcriptional responses. Current Opinion in Cell Biology, 1998, 10, 373-383.	2.6	565
24	NURD, a Novel Complex with Both ATP-Dependent Chromatin-Remodeling and Histone Deacetylase Activities. Molecular Cell, 1998, 2, 851-861.	4.5	891
25	The Dermatomyositis-Specific Autoantigen Mi2 Is a Component of a Complex Containing Histone Deacetylase and Nucleosome Remodeling Activities. Cell, 1998, 95, 279-289.	13.5	745
26	Structure, Organization, and Dynamics of Promyelocytic Leukemia Protein Nuclear Bodies. American Journal of Human Genetics, 1998, 63, 297-304.	2.6	156
27	Thyroid Hormone Receptor Coactivators and Corepressors. Thyroid, 1998, 8, 703-713.	2.4	112
28	Human Histone Deacetylase 2,HDAC2(HumanRPD3), Is Localized to 6q21 by Radiation Hybrid Mapping. Genomics, 1998, 52, 245-246.	1.3	19
29	Biochemical Methods for Analysis of Histone Deacetylases. Methods, 1998, 15, 323-331.	1.9	127
30	Identification of Bach2 as a B-cell-specific partner for small Maf proteins that negatively regulate the immunoglobulin heavy chain gene 3' enhancer. EMBO Journal, 1998, 17, 5734-5743.	3.5	162
31	THE CRITICAL ROLE OF CHROMOSOME TRANSLOCATIONS IN HUMAN LEUKEMIAS. Annual Review of Genetics, 1998, 32, 495-519.	3.2	368
32	A histone deacetylase corepressor complex regulates the Notch signal transduction pathway. Genes and Development, 1998, 12, 2269-2277.	2.7	514
33	Signaling by Tyrosine Kinases Negatively Regulates the Interaction between Transcription Factors and SMRT (Silencing Mediator of Retinoic Acid and Thyroid Hormone Receptor) Corepressor. Molecular Endocrinology, 1998, 12, 1161-1171.	3.7	50
34	Cloning and Characterization of the Mouse Histone Deacetylase-2 Gene. Journal of Biological Chemistry, 1998, 273, 28921-28930.	1.6	23
35	Components of the SMRT Corepressor Complex Exhibit Distinctive Interactions with the POZ Domain Oncoproteins PLZF, PLZF-RAR α , and BCL-6. Journal of Biological Chemistry, 1998, 273, 27695-27702.	1.6	150
36	Therapeutic Targeting of Transcription in Acute Promyelocytic Leukemia by Use of an Inhibitor of Histone Deacetylase. Journal of the National Cancer Institute, 1998, 90, 1621-1625.	3.0	499
37	Proteasomal regulation of nuclear receptor corepressor-mediated repression. Genes and Development, 1998, 12, 1775-1780.	2.7	207
38	Crystal structure of the BTB domain from PLZF. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 12123-12128.	3.3	264
39	The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Research, 1998, 26, 4645-4651.	6.5	216

#	ARTICLE	IF	CITATIONS
40	Chromatin, nuclear matrix and the cytoskeleton: role of cell structure in neoplastic transformation (review).. International Journal of Oncology, 1998, 13, 827-37.	1.4	12
41	ETO, a Target of t(8;21) in Acute Leukemia, Interacts with the N-CoR and mSin3 Corepressors. Molecular and Cellular Biology, 1998, 18, 7176-7184.	1.1	417
42	Aberrant Recruitment of the Nuclear Receptor Corepressor-Histone Deacetylase Complex by the Acute Myeloid Leukemia Fusion Partner ETO. Molecular and Cellular Biology, 1998, 18, 7185-7191.	1.1	466
43	Transcriptional Repression by the SMRT-mSin3 Corepressor: Multiple Interactions, Multiple Mechanisms, and a Potential Role for TFIIB. Molecular and Cellular Biology, 1998, 18, 5500-5510.	1.1	126
44	The Promyelocytic Leukemia Zinc Finger Protein Affects Myeloid Cell Growth, Differentiation, and Apoptosis. Molecular and Cellular Biology, 1998, 18, 5533-5545.	1.1	164
45	Depudecin makes a debut. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 3335-3337.	3.3	10
46	Transcriptional repression: lessons from thyroid hormone action and promyelocytic leukaemia. European Journal of Endocrinology, 1998, 139, 260-262.	1.9	0
47	Transformation of hematopoietic cells by the Ski oncoprotein involves repression of retinoic acid receptor signaling. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 11187-11192.	3.3	61
48	ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 10860-10865.	3.3	490
49	Deconstructing a Disease: RAR α , Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia. Blood, 1999, 93, 3167-3215.	0.6	990
50	Physical Interaction Between Retinoic Acid Receptor and Sp1: Mechanism for Induction of Urokinase by Retinoic Acid. Blood, 1999, 93, 4264-4276.	0.6	96
51	Constitutive Degradation of PML/RAR α Through the Proteasome Pathway Mediates Retinoic Acid Resistance. Blood, 1999, 93, 1477-1481.	0.6	72
52	1,25-Dihydroxyvitamin D3 Induces Differentiation of a Retinoic Acid-Resistant Acute Promyelocytic Leukemia Cell Line (UF-1) Associated With Expression of p21WAF1/CIP1 and p27KIP1. Blood, 1999, 93, 2225-2233.	0.6	90
53	Genetic Diagnosis and Molecular Monitoring in the Management of Acute Promyelocytic Leukemia. Blood, 1999, 94, 12-22.	0.6	193
54	Complete Remission of t(11;17) Positive Acute Promyelocytic Leukemia Induced by All-trans Retinoic Acid and Granulocyte Colony-Stimulating Factor. Blood, 1999, 94, 39-45.	0.6	76
55	Chromatin Remodeling and Leukemia: New Therapeutic Paradigms. Blood, 1999, 94, 417-428.	0.6	166
56	Overexpression of Wild-Type Retinoic Acid Receptor α (RAR α) Recapitulates Retinoic Acid-Sensitive Transformation of Primary Myeloid Progenitors by Acute Promyelocytic Leukemia RAR α -Fusion Genes. Blood, 1999, 94, 793-802.	0.6	95
57	Methylation, gene expression and the chromatin connection in cancer (review). International Journal of Molecular Medicine, 1999, 4, 333-50.	1.8	22

#	ARTICLE	IF	CITATIONS
58	The v-erbA oncogene (review).. International Journal of Molecular Medicine, 1999, 4, 351.	1.8	8
59	A novel retinoic acid-resistant acute promyelocytic leukemia model in vitro and in vivo (review).. International Journal of Molecular Medicine, 1999, 4, 359-64.	1.8	5
60	Histone deacetylase inhibitors: novel anticancer agents. Expert Opinion on Investigational Drugs, 1999, 8, 1611-1621.	1.9	21
61	The Nuclear Receptor Corepressor N-CoR Regulates Differentiation: N-CoR Directly Interacts with MyoD. Molecular Endocrinology, 1999, 13, 1155-1168.	3.7	67
62	Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 14807-14812.	3.3	340
63	The promyelocytic leukemia zinc finger (PLZF) protein binds DNA in a high molecular weight complex associated with cdc2 kinase. Nucleic Acids Research, 1999, 27, 4106-4113.	6.5	57
64	Re: Therapeutic Targeting of Transcription in Acute Promyelocytic Leukemia by Use of an Inhibitor of Histone Deacetylase Å RESPONSE. Journal of the National Cancer Institute, 1999, 91, 475-476.	3.0	6
65	Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARÅ and NPM-RARÅ. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 6318-6323.	3.3	92
66	Chromatin Remodeling and Transcriptional Regulation. Journal of the National Cancer Institute, 1999, 91, 1288-1294.	3.0	114
67	Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 2627-2632.	3.3	158
68	Nuclear Receptor Coregulators: Cellular and Molecular Biology*. Endocrine Reviews, 1999, 20, 321-344.	8.9	1,501
69	Unique forms of human and mouse nuclear receptor corepressor SMRT. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 2639-2644.	3.3	156
70	Transcriptional map of chromosome region 6q16â†'q21. Cytogenetic and Genome Research, 1999, 86, 263-266.	0.6	4
71	Retinoic Acid and Arsenic Synergize to Eradicate Leukemic Cells in a Mouse Model of Acute Promyelocytic Leukemia. Journal of Experimental Medicine, 1999, 189, 1043-1052.	4.2	303
72	SMRTE, a silencing mediator for retinoid and thyroid hormone receptors-extended isoform that is more related to the nuclear receptor corepressor. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 3519-3524.	3.3	119
73	Regulation of Lymphocyte Cell Fate Decisions and Lymphomagenesis by BCL-6. International Reviews of Immunology, 1999, 18, 381-403.	1.5	67
74	Acute progranulocytic leukaemia: a model for molecular medicine. Expert Opinion on Therapeutic Targets, 1999, 3, 135-150.	1.0	1
75	Retinoid Isomers Differ in the Ability to Induce Release of SMRT Corepressor from Retinoic Acid Receptor-Î±. Journal of Biological Chemistry, 1999, 274, 2885-2892.	1.6	20

#	ARTICLE	IF	CITATIONS
76	Recruitment of SMRT/N-CoR-mSin3A-HDAC-repressing complexes is not a general mechanism for BTB/POZ transcriptional repressors: The case of HIC-1 and gamma FBP-B. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 14831-14836.	3.3	105
77	Genomic sequence, structural organization, molecular evolution, and aberrant rearrangement of promyelocytic leukemia zinc finger gene. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 11422-11427.	3.3	47
78	Histone Deacetylase Inhibition Selectively Alters the Activity and Expression of Cell Cycle Proteins Leading to Specific Chromatin Acetylation and Antiproliferative Effects. Journal of Biological Chemistry, 1999, 274, 34940-34947.	1.6	352
79	Expression of Retinoid Receptor Genes and Proteins in Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 1999, 91, 1059-1066.	3.0	129
80	The Signal Transducer and Activator of Transcription STAT5b Gene Is a New Partner of Retinoic Acid Receptor α in Acute Promyelocytic-Like Leukaemia. Human Molecular Genetics, 1999, 8, 1741-1749.	1.4	265
81	THE AML1-ETO CHIMAERIC TRANSCRIPTION FACTOR IN ACUTE MYELOID LEUKAEMIA: BIOLOGY AND CLINICAL SIGNIFICANCE. British Journal of Haematology, 1999, 106, 296-308.	1.2	186
82	The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease. British Journal of Haematology, 1999, 106, 591-613.	1.2	88
83	A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RAR α and T18 oncoproteins. Nature Genetics, 1999, 23, 287-295.	9.4	127
84	Identification of the t(15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML/RAR α rearrangement in newly diagnosed AML. British Journal of Haematology, 1999, 105, 198-207.	1.2	43
85	The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature, 1999, 402, 93-96.	13.7	584
86	Atypical response to all-trans retinoic acid in a der(5)t(5;17) acute promyelocytic leukemia. Leukemia, 1999, 13, 862-868.	3.3	6
87	Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all-trans retinoic acid. Leukemia, 1999, 13, 1258-1265.	3.3	35
88	Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Leukemia, 1999, 13, 1316-1324.	3.3	142
89	Leukemogenesis by CBF oncoproteins. Leukemia, 1999, 13, 1932-1942.	3.3	96
90	Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia. Oncogene, 1999, 18, 633-641.	2.6	59
91	Retinoic acid, but not arsenic trioxide, degrades the PLZF/RAR α fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Oncogene, 1999, 18, 1113-1118.	2.6	97
92	A function of p21 during promyelocytic leukemia cell differentiation independent of CDK inhibition and cell cycle arrest. Oncogene, 1999, 18, 3235-3243.	2.6	86
93	Overexpressed BCL6 (LAZ3) oncoprotein triggers apoptosis, delays S ϕ phase progression and associates with replication foci. Oncogene, 1999, 18, 5063-5075.	2.6	62

#	ARTICLE	IF	CITATIONS
94	4HPR triggers apoptosis but not differentiation in retinoid sensitive and resistant human embryonal carcinoma cells through an RAR β independent pathway. <i>Oncogene</i> , 1999, 18, 5747-5755.	2.6	44
95	Acute promyelocytic leukemia: from treatment to genetics and back. <i>Oncogene</i> , 1999, 18, 5261-5267.	2.6	25
96	Formation of PML/RAR α high molecular weight nuclear complexes through the PML coiled-coil region is essential for the PML/RAR α -mediated retinoic acid response. <i>Oncogene</i> , 1999, 18, 6313-6321.	2.6	40
97	In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. <i>Oncogene</i> , 1999, 18, 5278-5292.	2.6	99
98	Role of retinoid receptors in the prevention and treatment of breast cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 1999, 4, 377-388.	1.0	35
99	Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A. <i>Oncogene</i> , 1999, 18, 925-934.	2.6	177
100	Repression by Ikaros and Aiolos is mediated through histone deacetylase complexes. <i>EMBO Journal</i> , 1999, 18, 3090-3100.	3.5	267
101	RAR-independent RXR signaling induces t(15;17) leukemia cell maturation. <i>EMBO Journal</i> , 1999, 18, 7011-7018.	3.5	104
102	Co-operative DNA binding by GAGA transcription factor requires the conserved BTB/POZ domain and reorganizes promoter topology. <i>EMBO Journal</i> , 1999, 18, 698-708.	3.5	155
103	The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. <i>EMBO Journal</i> , 1999, 18, 2449-2458.	3.5	295
104	Amide Analogues of Trichostatin A as Inhibitors of Histone Deacetylase and Inducers of Terminal Cell Differentiation. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 4669-4679.	2.9	178
105	Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 1999, 341, 1051-1062.	13.9	1,291
106	Molecular cloning and characterization of the mouse histone deacetylase 1 gene: integration of a retrovirus in 129SV mice. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1999, 1489, 365-373.	2.4	16
107	Molecular genetics of acute promyelocytic leukemia. <i>Trends in Genetics</i> , 1999, 15, 179-184.	2.9	107
108	Leukemia: the sophisticated subversion of hematopoiesis by nuclear receptor oncoproteins. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 1999, 1423, F15-F33.	3.3	7
109	Histone deacetylases: transcriptional repression with SINers and NuRDs. <i>Trends in Cell Biology</i> , 1999, 9, 193-198.	3.6	257
110	Inhibitors of Histone Deacetylase Suppress the Growth of MCF-7 Breast Cancer Cells. <i>Archiv Der Pharmazie</i> , 1999, 332, 353-357.	2.1	37
111	A selective retinoid with high activity against an androgen-resistant prostate cancer cell type. , 1999, 80, 272-278.		37

#	ARTICLE	IF	CITATIONS
112	Retinoids. Handbook of Experimental Pharmacology, 1999, , .	0.9	12
113	Cell-density (cycle) Dependent Silencer of the Rat Insulin-like Growth Factor Binding Protein-2 (IGFBP-2) Gene. Growth Factors, 1999, 16, 217-223.	0.5	5
114	Role of estrogen receptor ligand and estrogen response element sequence on interaction with chicken ovalbumin upstream promoter transcription factor (COUP-TF). Journal of Steroid Biochemistry and Molecular Biology, 1999, 71, 1-19.	1.2	39
115	Modification of Chromatin Structure by the Thyroid Hormone Receptor. Trends in Endocrinology and Metabolism, 1999, 10, 157-164.	3.1	36
116	Complex Complexes: Report of an NIDDK Workshop on Coactivators and Corepressors, Bethesda, USA, 15-16 December 1998. Trends in Endocrinology and Metabolism, 1999, 10, 286-289.	3.1	0
117	Nuclear receptor cofactors as chromatin remodelers. Current Opinion in Genetics and Development, 1999, 9, 499-504.	1.5	99
118	Histone acetylases and deacetylases in cell proliferation. Current Opinion in Genetics and Development, 1999, 9, 40-48.	1.5	572
119	Chromatin-modifying and -remodeling complexes. Current Opinion in Genetics and Development, 1999, 9, 148-151.	1.5	201
120	The PML nuclear bodies: actors or extras?. Current Opinion in Genetics and Development, 1999, 9, 362-367.	1.5	122
121	SMRTER, a Drosophila Nuclear Receptor Coregulator, Reveals that EcR-Mediated Repression Is Critical for Development. Molecular Cell, 1999, 4, 175-186.	4.5	195
122	Chromatin rearrangements during nucleotide excision repair. Biochimie, 1999, 81, 45-52.	1.3	33
123	Evolutionary divergence in the broad complex, tramtrack and bric À brac/poxviruses and zinc finger domain from the candidate tumor suppressor gene hypermethylated in cancer. FEBS Letters, 1999, 451, 253-256.	1.3	8
124	Regulation of Hormone-Induced Histone Hyperacetylation and Gene Activation via Acetylation of an Acetylase. Cell, 1999, 98, 675-686.	13.5	626
125	Organization of chromatin in cancer cells: role of signalling pathways. Biochemistry and Cell Biology, 1999, 77, 265-275.	0.9	37
126	Net, a negative Ras-switchable TCF, contains a second inhibition domain, the CID, that mediates repression through interactions with CtBP and de-acetylation. EMBO Journal, 1999, 18, 3392-3403.	3.5	139
127	Different Types of Maize Histone Deacetylases Are Distinguished by a Highly Complex Substrate and Site Specificity. Biochemistry, 1999, 38, 6769-6773.	1.2	75
128	Fold prediction and evolutionary analysis of the POZ domain: structural and evolutionary relationship with the potassium channel tetramerization domain 1 1Edited by F. Cohen. Journal of Molecular Biology, 1999, 285, 1353-1361.	2.0	158
129	Analysis of the Modulation of Transcriptional Activity in Myelopoiesis and Leukemogenesis. Methods, 1999, 17, 231-237.	1.9	32

#	ARTICLE	IF	CITATIONS
130	Identification and Gene Structure of a Novel Human PLZF-Related Transcription Factor Gene, TZFP. <i>Biochemical and Biophysical Research Communications</i> , 1999, 264, 789-795.	1.0	28
131	Transcriptional Repression of Stat6-Dependent Interleukin-4-Induced Genes by BCL-6: Specific Regulation of IÉ Transcription and Immunoglobulin E Switching. <i>Molecular and Cellular Biology</i> , 1999, 19, 7264-7275.	1.1	184
132	The Zinc Finger-Associated SCAN Box Is a Conserved Oligomerization Domain. <i>Molecular and Cellular Biology</i> , 1999, 19, 8526-8535.	1.1	86
133	The Catenin p120 ^{ctn} Interacts with Kaiso, a Novel BTB/POZ Domain Zinc Finger Transcription Factor. <i>Molecular and Cellular Biology</i> , 1999, 19, 3614-3623.	1.1	393
134	Histone Deacetylase 1 Can Repress Transcription by Binding to Sp1. <i>Molecular and Cellular Biology</i> , 1999, 19, 5504-5511.	1.1	387
135	A Novel Role for Helix 12 of Retinoid X Receptor in Regulating Repression. <i>Molecular and Cellular Biology</i> , 1999, 19, 6448-6457.	1.1	102
136	Retinoid X Receptor (RXR) Agonist-Induced Activation of Dominant-Negative RXR-Retinoic Acid Receptor ±403 Heterodimers Is Developmentally Regulated during Myeloid Differentiation. <i>Molecular and Cellular Biology</i> , 1999, 19, 3372-3382.	1.1	32
137	Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. <i>Genes and Development</i> , 1999, 13, 1924-1935.	2.7	951
138	Extramedullary Disease in Acute Promyelocytic Leukemia. <i>Leukemia and Lymphoma</i> , 1999, 33, 219-229.	0.6	75
139	Signal transduction pathways and the modification of chromatin structure. <i>Progress in Molecular Biology and Translational Science</i> , 2000, 65, 299-340.	1.9	32
140	Chromatin organisation and human disease. <i>Expert Opinion on Therapeutic Targets</i> , 2000, 4, 665-685.	1.0	22
141	Cloning and characterization of a novel human histone deacetylase, HDAC8. <i>Biochemical Journal</i> , 2000, 350, 199.	1.7	46
142	Cloning and characterization of a novel human histone deacetylase, HDAC8. <i>Biochemical Journal</i> , 2000, 350, 199-205.	1.7	156
143	HDAC1, a Histone Deacetylase, Forms a Complex with Hus1 and Rad9, Two G2/M Checkpoint Rad Proteins. <i>Journal of Biological Chemistry</i> , 2000, 275, 27909-27916.	1.6	65
144	High levels of intracellular polyamines promote histone acetyltransferase activity resulting in chromatin hyperacetylation. <i>Journal of Cellular Biochemistry</i> , 2000, 77, 345-360.	1.2	73
145	Histone deacetylases, transcriptional control, and cancer. <i>Journal of Cellular Physiology</i> , 2000, 184, 1-16.	2.0	576
146	When the band begins to play: Histone acetylation caught in the crossfire of gene control. , 2000, 27, 268-271.		21
147	Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. <i>Medical and Pediatric Oncology</i> , 2000, 35, 577-581.	1.0	57

#	ARTICLE	IF	CITATIONS
148	Differential display as an approach to study differentiation and differentiation therapy in AML. <i>Hematological Oncology</i> , 2000, 18, 129-140.	0.8	3
149	Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-transretinoic acid. <i>British Journal of Haematology</i> , 2000, 108, 696-702.	1.2	84
150	Transcriptional regulation of cellular transformation. <i>Nature Medicine</i> , 2000, 6, 742-744.	15.2	24
151	Measles vaccines – A positive step toward eradicating a negative strand. <i>Nature Medicine</i> , 2000, 6, 744-745.	15.2	9
152	The impact of differential binding of wild-type RAR α , PML-, PLZF- and NPM-RAR α fusion proteins towards transcriptional co-activator, RIP-140, on retinoic acid responses in acute promyelocytic leukemia. <i>Leukemia</i> , 2000, 14, 77-83.	3.3	29
153	New agents for acute myelogenous leukemia. <i>Leukemia</i> , 2000, 14, 488-490.	3.3	15
154	Differentiation therapy in acute myelogenous leukemia (non-APL). <i>Leukemia</i> , 2000, 14, 491-496.	3.3	66
155	Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies. <i>Leukemia</i> , 2000, 14, 1833-1849.	3.3	131
156	Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β 2 promoter in breast cancer cells. <i>Oncogene</i> , 2000, 19, 1556-1563.	2.6	188
157	Human endogenous retrovirus protein cORF supports cell transformation and associates with the promyelocytic leukemia zinc finger protein. <i>Oncogene</i> , 2000, 19, 4328-4336.	2.6	111
158	Colocalization and heteromerization between the two human oncogene POZ/zinc finger proteins, LAZ3 (BCL6) and PLZF. <i>Oncogene</i> , 2000, 19, 6240-6250.	2.6	66
159	PML and the oncogenic nuclear domains in regulating transcriptional repression. <i>Current Opinion in Cell Biology</i> , 2000, 12, 641-644.	2.6	18
160	NURD-complex genes antagonise Ras-induced vulval development in <i>Caenorhabditis elegans</i> . <i>Current Biology</i> , 2000, 10, 223-226.	1.8	146
161	NuRD and SIN3. <i>Trends in Genetics</i> , 2000, 16, 351-356.	2.9	356
162	Regulation of matrix attachment region-dependent, lymphocyte-restricted transcription through differential localization within promyelocytic leukemia nuclear bodies. <i>EMBO Journal</i> , 2000, 19, 4123-4133.	3.5	53
163	P/CAF-mediated acetylation regulates the function of the basic helix-loop-helix transcription factor TAL1/SCL. <i>EMBO Journal</i> , 2000, 19, 6792-6803.	3.5	77
164	Molecular biology of leukemia. <i>Current Oncology Reports</i> , 2000, 2, 123-131.	1.8	1
165	Mechanisms of all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells. <i>Journal of Biosciences</i> , 2000, 25, 275-284.	0.5	57

#	ARTICLE	IF	CITATIONS
166	CREB-binding protein and p300: molecular integrators of hematopoietic transcription. <i>Blood</i> , 2000, 95, 745-755.	0.6	228
167	Leukemia initiated by PML/RAR \pm : the PML domain plays a critical role while retinoic acid \hat{e} mediated transactivation is dispensable. <i>Blood</i> , 2000, 95, 1541-1550.	0.6	91
168	The t(5;17) acute promyelocytic leukemia fusion protein NPM-RAR interacts with co-repressor and co-activator proteins and exhibits both positive and negative transcriptional properties. <i>Blood</i> , 2000, 95, 2683-2690.	0.6	56
169	Differentiation-independent retinoid induction of folate receptor type \hat{I}^2 , a potential tumor target in myeloid leukemia. <i>Blood</i> , 2000, 96, 3529-3536.	0.6	70
170	PML/RAR \pm fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype. <i>Blood</i> , 2000, 96, 1531-1537.	0.6	81
171	Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia \hat{a} associated TEL-AML1 oncoprotein. <i>Blood</i> , 2000, 96, 2557-2561.	0.6	106
172	Altered ligand binding and transcriptional regulation by mutations in the PML/RAR \pm ligand-binding domain arising in retinoic acid \hat{a} resistant patients with acute promyelocytic leukemia. <i>Blood</i> , 2000, 96, 3200-3208.	0.6	65
173	AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein. <i>Blood</i> , 2000, 96, 3939-3947.	0.6	59
174	Ligand-inducible interaction of the DRIP/TRAP coactivator complex with retinoid receptors in retinoic acid \hat{a} sensitive and \hat{a} resistant acute promyelocytic leukemia cells. <i>Blood</i> , 2000, 96, 2233-2239.	0.6	22
175	The Role of Retinoic Acid Receptors in Myeloid Differentiation. , 0, , 149-161.		0
176	The Role of Ikaros Family Genes in Lymphocyte Differentiation and Proliferation. , 0, , 181-199.		0
177	The Acetyltransferases CBP and p300: Molecular Integrators of Hematopoietic Transcription Involved in Chromosomal Translocations. , 0, , 497-517.		0
178	Gene expression networks underlying retinoic acid \hat{a} induced differentiation of acute promyelocytic leukemia cells. <i>Blood</i> , 2000, 96, 1496-1504.	0.6	209
179	Suberoylanilide Hydroxamic Acid as a Potential Therapeutic Agent for Human Breast Cancer Treatment. <i>Molecular Medicine</i> , 2000, 6, 849-866.	1.9	149
180	Histone Acetylation Modifiers in the Pathogenesis of Malignant Disease. <i>Molecular Medicine</i> , 2000, 6, 623-644.	1.9	177
181	Molecular Diagnosis in Pediatric Acute Leukemias. <i>Clinics in Laboratory Medicine</i> , 2000, 20, 139-182.	0.7	11
182	Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1210-1216.	3.0	1,099
183	Potential of GATA-2 Activity through Interactions with the Promyelocytic Leukemia Protein (PML) and the t(15;17)-Generated PML-Retinoid Acid Receptor \hat{I}^2 Oncoprotein. <i>Molecular and Cellular Biology</i> , 2000, 20, 6276-6286.	1.1	54

#	ARTICLE	IF	CITATIONS
184	Cloning and Characterization of a Novel Human Class I Histone Deacetylase That Functions as a Transcription Repressor. <i>Journal of Biological Chemistry</i> , 2000, 275, 15254-15264.	1.6	244
185	mSin3A Regulates Murine Erythroleukemia Cell Differentiation through Association with the TAL1 (or) Tj ETQq1 1 0,784314 rgBT /Overl 1.1 94	1.1	94
186	Induction of Differentiation and Apoptosisâ€™ A Possible Strategy in the Treatment of Adult Acute Myelogenous Leukemia. <i>Oncologist</i> , 2000, 5, 454-462.	1.9	40
187	The Role of CBP in Estrogen Receptor Cross-Talk with Nuclear Factor-Î²B in HepG2 Cells. <i>Endocrinology</i> , 2000, 141, 3403-3411.	1.4	130
188	Expression of MTA1, a metastasis-associated gene with histone deacetylase activity in pancreatic cancer.. <i>International Journal of Oncology</i> , 2000, 16, 1211-4.	1.4	30
189	Nuclear Hormone Receptor Coregulators In Action: Diversity For Shared Tasks. <i>Molecular Endocrinology</i> , 2000, 14, 329-347.	3.7	350
190	Dissecting the molecular mechanism of nuclear receptor action: transcription coactivators and corepressors. <i>Experimental and Molecular Medicine</i> , 2000, 32, 53-60.	3.2	6
191	Detection of t(15;17)(q24;q21), inv(16)/t(16;16)(p13;q22), and t(8;21)(q22;q22) Anomalies in Acute Myeloid Leukemias. , 2001, 49, 115-145.		2
192	Retinoids in chemoprevention and differentiation therapy. <i>Carcinogenesis</i> , 2000, 21, 1271-1279.	1.3	234
193	The ETO Protein Disrupted in t(8;21)-Associated Acute Myeloid Leukemia Is a Corepressor for the Promyelocytic Leukemia Zinc Finger Protein. <i>Molecular and Cellular Biology</i> , 2000, 20, 2075-2086.	1.1	134
194	Transcriptional Repression by Blimp-1 (PRDI-BF1) Involves Recruitment of Histone Deacetylase. <i>Molecular and Cellular Biology</i> , 2000, 20, 2592-2603.	1.1	306
195	Chromatin modification and disease. <i>Journal of Medical Genetics</i> , 2000, 37, 905-915.	1.5	17
196	ATP-Dependent Chromatin Remodeling by the Cockayne Syndrome B DNA Repair-Transcription-Coupling Factor. <i>Molecular and Cellular Biology</i> , 2000, 20, 7643-7653.	1.1	334
197	In-Depth Mutational Analysis of the Promyelocytic Leukemia Zinc Finger BTB/POZ Domain Reveals Motifs and Residues Required for Biological and Transcriptional Functions. <i>Molecular and Cellular Biology</i> , 2000, 20, 6550-6567.	1.1	167
198	Silencing Mediator of Retinoic Acid and Thyroid Hormone Receptors, as a Novel Transcriptional Corepressor Molecule of Activating Protein-1, Nuclear Factor-Î²B, and Serum Response Factor. <i>Journal of Biological Chemistry</i> , 2000, 275, 12470-12474.	1.6	119
199	Coâ€™repressors 2000. <i>FASEB Journal</i> , 2000, 14, 1876-1888.	0.2	193
200	Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 10173-10178.	3.3	193
201	Set Domain-Dependent Regulation of Transcriptional Silencing and Growth Control by SLIV39H1, a Mammalian Ortholog of <i>Drosophila</i> Su(var)3-9. <i>Molecular and Cellular Biology</i> , 2000, 20, 4900-4909.	1.1	103

#	ARTICLE	IF	CITATIONS
202	Sequestration and Inhibition of Daxx-Mediated Transcriptional Repression by PML. <i>Molecular and Cellular Biology</i> , 2000, 20, 1784-1796.	1.1	326
203	A Dominant-negative Peroxisome Proliferator-activated Receptor $\hat{1}^3$ (PPAR $\hat{1}^3$) Mutant Is a Constitutive Repressor and Inhibits PPAR $\hat{1}^3$ -mediated Adipogenesis. <i>Journal of Biological Chemistry</i> , 2000, 275, 5754-5759.	1.6	249
204	A Novel Nuclear Receptor Corepressor Complex, N-CoR, Contains Components of the Mammalian SWI/SNF Complex and the Corepressor KAP-1. <i>Journal of Biological Chemistry</i> , 2000, 275, 40463-40470.	1.6	279
205	Molecular Cloning and Characterization of a Novel Human Gene Containing Ankyrin Repeat and Double BTB/POZ Domain. <i>Biochemical and Biophysical Research Communications</i> , 2000, 273, 991-996.	1.0	13
206	Transcription therapy for acute promyelocytic leukaemia. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 329-346.	1.9	8
207	Resistance to thyroid hormone (RTH) syndrome reveals novel determinants regulating interaction of T3 receptor with corepressor. <i>Molecular and Cellular Endocrinology</i> , 2000, 159, 109-124.	1.6	31
208	Transcriptional Repression by Nuclear Hormone Receptors. <i>Trends in Endocrinology and Metabolism</i> , 2000, 11, 6-10.	3.1	268
209	Two Critical Hits for Promyelocytic Leukemia. <i>Molecular Cell</i> , 2000, 6, 1131-1141.	4.5	146
210	Oligomerization of RAR and AML1 Transcription Factors as a Novel Mechanism of Oncogenic Activation. <i>Molecular Cell</i> , 2000, 5, 811-820.	4.5	273
211	Acquisition of Oncogenic Potential by RAR Chimeras in Acute Promyelocytic Leukemia through Formation of Homodimers. <i>Molecular Cell</i> , 2000, 5, 821-830.	4.5	223
212	Location and function of critical genes in leukemogenesis inferred from cytogenetic abnormalities in hematologic malignancies. <i>Seminars in Hematology</i> , 2000, 37, 412-419.	1.8	3
213	White cells 2: impact of understanding the molecular basis of haematological malignant disorders on clinical practice. <i>Lancet</i> , The, 2000, 355, 1447-1453.	6.3	4
214	Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 2923-2934.	1.9	92
215	Retinoic Acid Receptor $\hat{1}\pm$ (RAR $\hat{1}\pm$) Mutations in Human Leukemia. <i>Leukemia and Lymphoma</i> , 2000, 39, 271-282.	0.6	10
216	A Novel Member of the BTB/POZ Family, PATZ, Associates with the RNF4 RING Finger Protein and Acts as a Transcriptional Repressor. <i>Journal of Biological Chemistry</i> , 2000, 275, 7894-7901.	1.6	83
217	P21-dependent G1arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. <i>British Journal of Cancer</i> , 2000, 83, 817-825.	2.9	272
218	The Mechanism of Action of Thyroid Hormones. <i>Annual Review of Physiology</i> , 2000, 62, 439-466.	5.6	605
219	Thyroid hormone receptor, v-erbA, and chromatin. <i>Vitamins and Hormones</i> , 2000, 58, 449-492.	0.7	21

#	ARTICLE	IF	CITATIONS
220	Molecular genetics of acute myeloid leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2001, 14, 49-64.	0.7	122
221	Chromatin Remodelling Machines. , 0, , 146-171.		0
222	Mammalian Histone Deacetylase 1 Protein Is Posttranslationally Modified by Phosphorylation. <i>Biochemical and Biophysical Research Communications</i> , 2001, 283, 445-453.	1.0	61
223	Histone Deacetylase Inhibitors: Development of Suberoylanilide Hydroxamic Acid (SAHA) for the Treatment of Cancers. <i>Blood Cells, Molecules, and Diseases</i> , 2001, 27, 260-264.	0.6	80
224	The BTB/POZ Domain of the Regulatory Proteins Bric Å brac 1 (BAB1) and Bric Å brac 2 (BAB2) Interacts with the Novel Drosophila TAFII Factor BIP2/dTAFII155. <i>Developmental Biology</i> , 2001, 237, 368-380.	0.9	35
225	Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells. <i>Cancer Letters</i> , 2001, 163, 103-108.	3.2	65
226	A new functional domain of Bcl6 family that recruits histone deacetylases. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2001, 1540, 188-200.	1.9	41
227	Prospects for prevention and treatment of cancer with selective PPAR γ modulators (SPARMs). <i>Trends in Molecular Medicine</i> , 2001, 7, 395-400.	3.5	140
228	Histone deacetylase as a therapeutic target. <i>Trends in Endocrinology and Metabolism</i> , 2001, 12, 294-300.	3.1	238
229	Role of PML and PML-RAR α in Mad-Mediated Transcriptional Repression. <i>Molecular Cell</i> , 2001, 7, 1233-1243.	4.5	137
230	Acute promyelocytic leukemia with a PLZF-RAR α fusion protein. <i>Seminars in Hematology</i> , 2001, 38, 37-41.	1.8	22
231	Effects of the acute myeloid leukemia-associated fusion proteins on nuclear architecture. <i>Seminars in Hematology</i> , 2001, 38, 42-53.	1.8	17
232	Analysis of the molecular genetics of acute promyelocytic leukemia in mouse models. <i>Seminars in Hematology</i> , 2001, 38, 54-70.	1.8	28
233	Future perspectives for acute promyelocytic leukemia therapy. <i>Seminars in Hematology</i> , 2001, 38, 86-91.	1.8	2
234	Leucemias agudas mieloblásticas. Clasificación. Etiopatogenia. Características citológicas, inmunofenotípicas y moleculares. <i>Medicine</i> , 2001, 8, 2881-2889.	0.0	0
235	Fluorescence-Labeled Octapeptides as Substrates for Histone Deacetylase. <i>Bioconjugate Chemistry</i> , 2001, 12, 51-55.	1.8	15
237	Genomic organization and refined mapping of the human nuclear corepressor 2 (NCOR2)/ silencing mediator of retinoid and thyroid hormone receptor (SMRT) gene on chromosome 12q24.3. <i>Cytogenetic and Genome Research</i> , 2001, 92, 217-220.	0.6	11
238	Nuclear Hormone Receptors and Gene Expression. <i>Physiological Reviews</i> , 2001, 81, 1269-1304.	13.1	1,296

#	ARTICLE	IF	CITATIONS
239	Positive and negative regulation of granulopoiesis by endogenous RAR β . <i>Blood</i> , 2001, 97, 1314-1320.	0.6	122
240	The corepressor CtBP interacts with Evi-1 to repress transforming growth factor β signaling. <i>Blood</i> , 2001, 97, 2815-2822.	0.6	214
241	The acute promyelocytic leukemia-associated protein, promyelocytic leukemia zinc finger, regulates 1,25-dihydroxyvitamin D $_3$ -induced monocytic differentiation of U937 cells through a physical interaction with vitamin D $_3$ receptor. <i>Blood</i> , 2001, 98, 3290-3300.	0.6	52
242	Rabaptin-5 is a novel fusion partner to platelet-derived growth factor β receptor in chronic myelomonocytic leukemia. <i>Blood</i> , 2001, 98, 2518-2525.	0.6	134
243	Transcriptional coregulators of the nuclear receptor superfamily: coactivators and corepressors. <i>Cellular and Molecular Life Sciences</i> , 2001, 58, 289-297.	2.4	116
244	Histone acetylation: plants and fungi as model systems for the investigation of histone deacetylases. <i>Cellular and Molecular Life Sciences</i> , 2001, 58, 704-720.	2.4	39
245	Histone acetylation and disease. <i>Cellular and Molecular Life Sciences</i> , 2001, 58, 728-736.	2.4	293
246	The biology of acute promyelocytic leukemia. <i>Current Oncology Reports</i> , 2001, 3, 209-216.	1.8	14
247	The leukaemia-associated transcription factors EVI-1 and MDS1/EVI1 repress transcription and interact with histone deacetylase. <i>British Journal of Haematology</i> , 2001, 114, 566-573.	1.2	45
248	Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17). <i>British Journal of Haematology</i> , 2001, 115, 287-297.	1.2	84
249	Design and synthesis of a novel class of histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001, 11, 2847-2850.	1.0	72
250	Genetic lesions and perturbation of chromatin architecture: A road to cell transformation. <i>Journal of Cellular Biochemistry</i> , 2001, 82, 310-325.	1.2	19
251	Trichostatin A inhibits κ -casein expression in mammary epithelial cells. <i>Journal of Cellular Biochemistry</i> , 2001, 83, 660-670.	1.2	23
252	Both normal and leukemic B lymphocytes express multiple isoforms of the human Aiolos gene. <i>European Journal of Immunology</i> , 2001, 31, 3469-3474.	1.6	24
253	Improvement and Validation of the Fluorescence-Based Histone Deacetylase Assay Using an Internal Standard. <i>Archiv Der Pharmazie</i> , 2001, 334, 248-252.	2.1	22
254	Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2001, 6, 183-192.	1.0	71
255	Genes, chromatin, and breast cancer: an epigenetic tale. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2001, 6, 169-182.	1.0	39
256	Functional interaction of STAT5 and nuclear receptor co-repressor SMRT: implications in negative regulation of STAT5-dependent transcription. <i>EMBO Journal</i> , 2001, 20, 6836-6844.	3.5	104

#	ARTICLE	IF	CITATIONS
257	Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. <i>EMBO Journal</i> , 2001, 20, 6969-6978.	3.5	1,607
258	A functionally active RAR α nuclear receptor is expressed in retinoic acid non responsive early myeloblastic cell lines. <i>Cell Death and Differentiation</i> , 2001, 8, 70-82.	5.0	6
259	Transcription factors and translocations in lymphoid and myeloid leukemia. <i>Leukemia</i> , 2001, 15, 313-331.	3.3	47
260	Synergistic growth inhibition of prostate cancer cells by 1 α ,25 Dihydroxyvitamin D3 and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. <i>Oncogene</i> , 2001, 20, 1860-1872.	2.6	122
261	Transcription therapy for cancer. <i>Oncogene</i> , 2001, 20, 3116-3127.	2.6	158
262	Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?. <i>Oncogene</i> , 2001, 20, 3110-3115.	2.6	191
263	In vivo analysis of the molecular genetics of acute promyelocytic leukemia. <i>Oncogene</i> , 2001, 20, 5726-5735.	2.6	61
264	Common themes in the pathogenesis of acute myeloid leukemia. <i>Oncogene</i> , 2001, 20, 5680-5694.	2.6	72
265	Function of RAR α during the maturation of neutrophils. <i>Oncogene</i> , 2001, 20, 7178-7185.	2.6	80
266	Biological features of primary APL blasts: their relevance to the understanding of granulopoiesis, leukemogenesis and patient management. <i>Oncogene</i> , 2001, 20, 7154-7160.	2.6	15
267	Translocations of the RAR α gene in acute promyelocytic leukemia. <i>Oncogene</i> , 2001, 20, 7186-7203.	2.6	206
268	APL, a model disease for cancer therapies?. <i>Oncogene</i> , 2001, 20, 7136-7139.	2.6	20
269	Pathways of retinoic acid- or arsenic trioxide-induced PML/RAR α catabolism, role of oncogene degradation in disease remission. <i>Oncogene</i> , 2001, 20, 7257-7265.	2.6	143
270	Transcriptional regulation in acute promyelocytic leukemia. <i>Oncogene</i> , 2001, 20, 7204-7215.	2.6	153
271	The theory of APL. <i>Oncogene</i> , 2001, 20, 7216-7222.	2.6	103
272	Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. <i>Nature Cell Biology</i> , 2001, 3, 30-37.	4.6	354
273	The promise of retinoids to fight against cancer. <i>Nature Reviews Cancer</i> , 2001, 1, 181-193.	12.8	712
274	In vivo Effects of a Histone Deacetylase Inhibitor, FK228, on Human Acute Promyelocytic Leukemia in NOD/Shi-scid/scid Mice. <i>Japanese Journal of Cancer Research</i> , 2001, 92, 529-536.	1.7	53

#	ARTICLE	IF	CITATIONS
275	Emerging roles for chromatin remodeling in cancer biology. <i>Trends in Cell Biology</i> , 2001, 11, S15-S21.	3.6	46
276	Emerging roles for chromatin remodeling in cancer biology. <i>Trends in Cell Biology</i> , 2001, 11, S15-S21.	3.6	59
277	Structure of Histone Deacetylases. <i>Structure</i> , 2001, 9, 1127-1133.	1.6	87
278	Novel mutation in the PML/RAR α chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia. <i>Experimental Hematology</i> , 2001, 29, 864-872.	0.2	37
279	Chromatin modifiers and tumor suppression. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2001, 1551, M1-M10.	3.3	14
280	Ca ²⁺ /Calmodulin-dependent Protein Kinase IV Stimulates Nuclear Factor- κ B Transactivation via Phosphorylation of the p65 Subunit. <i>Journal of Biological Chemistry</i> , 2001, 276, 20005-20010.	1.6	74
281	Arsenic Trioxide Is a Potent Inhibitor of the Interaction of SMRT Corepressor with Its Transcription Factor Partners, Including the PML-Retinoic Acid Receptor α Oncoprotein Found in Human Acute Promyelocytic Leukemia. <i>Molecular and Cellular Biology</i> , 2001, 21, 7172-7182.	1.1	59
282	The Growth Suppressor PML Represses Transcription by Functionally and Physically Interacting with Histone Deacetylases. <i>Molecular and Cellular Biology</i> , 2001, 21, 2259-2268.	1.1	138
283	Histone Deacetylase 1 Phosphorylation Promotes Enzymatic Activity and Complex Formation. <i>Journal of Biological Chemistry</i> , 2001, 276, 47733-47741.	1.6	220
284	Histone deacetylase-dependent transcriptional repression by pRB in yeast occurs independently of interaction through the LXCXE binding cleft. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 8720-8725.	3.3	26
285	Biochemical Analysis of Transcriptional Repression by <i>Drosophila</i> Histone Deacetylase 1. <i>Journal of Biological Chemistry</i> , 2001, 276, 12497-12500.	1.6	18
286	Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome. <i>Human Molecular Genetics</i> , 2001, 10, 1071-1076.	1.4	143
287	Inhibition of Histone Deacetylation Induces Constitutive Derepression of the Beta Interferon Promoter and Confers Antiviral Activity. <i>Journal of Virology</i> , 2001, 75, 3444-3452.	1.5	54
288	All in the Family: the BTB/POZ, KRAB, and SCAN Domains. <i>Molecular and Cellular Biology</i> , 2001, 21, 3609-3615.	1.1	319
289	PSF Is a Novel Corepressor That Mediates Its Effect through Sin3A and the DNA Binding Domain of Nuclear Hormone Receptors. <i>Molecular and Cellular Biology</i> , 2001, 21, 2298-2311.	1.1	158
290	Oligomerization of ETO Is Obligatory for Corepressor Interaction. <i>Molecular and Cellular Biology</i> , 2001, 21, 156-163.	1.1	100
291	Determinants of CoRNR-Dependent Repression Complex Assembly on Nuclear Hormone Receptors. <i>Molecular and Cellular Biology</i> , 2001, 21, 1747-1758.	1.1	126
292	Silencing Mediator for Retinoid and Thyroid Hormone Receptors Interacts with Octamer Transcription Factor-1 and Acts as a Transcriptional Repressor. <i>Journal of Biological Chemistry</i> , 2001, 276, 9720-9725.	1.6	31

#	ARTICLE	IF	CITATIONS
293	Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia. <i>Human Molecular Genetics</i> , 2001, 10, 769-775.	1.4	89
294	Histone Acetylation / Deacetylation and Cancer: An “Open” and “Shut” Case?. <i>Current Molecular Medicine</i> , 2001, 1, 401-429.	0.6	87
295	Treatment of Acute Promyelocytic Leukemia with ATRA and As₂O₃: A Model of Molecular. <i>Cancer Biology and Therapy</i> , 2002, 1, 614-620.	1.5	73
296	External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 12747-12752.	3.3	63
297	Major Phase I Biotransformation Pathways of Trichostatin A in Rat Hepatocytes and in Rat and Human Liver Microsomes. <i>Drug Metabolism and Disposition</i> , 2002, 30, 1320-1328.	1.7	52
298	UBE1L is a retinoid target that triggers PML/RAR α degradation and apoptosis in acute promyelocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 3806-3811.	3.3	117
299	Class II Histone Deacetylases Are Directly Recruited by BCL6 Transcriptional Repressor. <i>Journal of Biological Chemistry</i> , 2002, 277, 22045-22052.	1.6	155
300	Critical Residues within the BTB Domain of PLZF and Bcl-6 Modulate Interaction with Corepressors. <i>Molecular and Cellular Biology</i> , 2002, 22, 1804-1818.	1.1	200
301	Competitive Cofactor Recruitment by Orphan Receptor Hepatocyte Nuclear Factor 4 α 1: Modulation by the F Domain. <i>Molecular and Cellular Biology</i> , 2002, 22, 1626-1638.	1.1	86
302	Human Papilloma Virus 16 E6 Oncoprotein Inhibits Retinoic X Receptor-mediated Transactivation by Targeting Human ADA3 Coactivator. <i>Journal of Biological Chemistry</i> , 2002, 277, 45611-45618.	1.6	55
303	The p120 ^{ctn} -binding partner Kaiso is a bi-modal DNA-binding protein that recognizes both a sequence-specific consensus and methylated CpG dinucleotides. <i>Nucleic Acids Research</i> , 2002, 30, 2911-2919.	6.5	243
304	Identification of Mammalian Sds3 as an Integral Component of the Sin3/Histone Deacetylase Corepressor Complex. <i>Molecular and Cellular Biology</i> , 2002, 22, 2743-2750.	1.1	105
305	Attomole Detection of in Vivo Protein Targets of Benzene in Mice. <i>Molecular and Cellular Proteomics</i> , 2002, 1, 885-895.	2.5	30
306	Advances in the Treatment of Relapsed Acute Promyelocytic Leukemia. <i>Acta Haematologica</i> , 2002, 107, 1-17.	0.7	29
307	TNF α induces acetylation of p53 but attenuates its transcriptional activation in rheumatoid synoviocytes. <i>International Journal of Molecular Medicine</i> , 2002, 10, 269.	1.8	4
308	A novel therapeutic technology of specific RNA inhibition for acute promyelocytic leukemia: Improved design of maxizymes against PML/RAR α mRNA. <i>International Journal of Oncology</i> , 2002, 20, 127.	1.4	3
309	Identifying Molecular Targets Mediating the Anticancer Activity of Histone Deacetylase Inhibitors: A Work in Progress. <i>Current Cancer Drug Targets</i> , 2002, 2, 337-353.	0.8	25
310	Chromosomal Translocations in Hematologic Malignancies. <i>Current Genomics</i> , 2002, 3, 313-334.	0.7	2

#	ARTICLE	IF	CITATIONS
311	The emergence of resistance to targeted cancer therapeutics. <i>Pharmacogenomics</i> , 2002, 3, 603-623.	0.6	26
312	ASB-2 Inhibits Growth and Promotes Commitment in Myeloid Leukemia Cells. <i>Journal of Biological Chemistry</i> , 2002, 277, 218-224.	1.6	75
313	Androgen Receptor Acetylation Governs trans Activation and MEKK1-Induced Apoptosis without Affecting In Vitro Sumoylation and trans -Repression Function. <i>Molecular and Cellular Biology</i> , 2002, 22, 3373-3388.	1.1	155
314	POZ Domain Transcription Factor, FBI-1, Represses Transcription of ADH5/FDH by Interacting with the Zinc Finger and Interfering with DNA Binding Activity of Sp1. <i>Journal of Biological Chemistry</i> , 2002, 277, 26761-26768.	1.6	90
315	The Drosophila transcription factor tramtrack (TTK) interacts with Trithorax-like (GAGA) and represses GAGA-mediated activation. <i>Nucleic Acids Research</i> , 2002, 30, 4406-4413.	6.5	44
316	SUMO-1 Modification of Histone Deacetylase 1 (HDAC1) Modulates Its Biological Activities. <i>Journal of Biological Chemistry</i> , 2002, 277, 23658-23663.	1.6	199
317	Advances in the Management of Acute Promyelocytic Leukemia and Other Hematologic Malignancies with Arsenic Trioxide. <i>Oncologist</i> , 2002, 7, 1-13.	1.9	26
318	The LIM-only Protein DRAL/FHL2 Interacts with and Is a Corepressor for the Promyelocytic Leukemia Zinc Finger Protein. <i>Journal of Biological Chemistry</i> , 2002, 277, 37045-37053.	1.6	67
319	Role of peroxisome proliferator-activated receptor- β in hematologic malignancies. <i>Current Opinion in Hematology</i> , 2002, 9, 294-302.	1.2	31
320	Histone deacetylase inhibitors in cancer treatment. <i>Anti-Cancer Drugs</i> , 2002, 13, 1-13.	0.7	280
321	Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. <i>Blood</i> , 2002, 99, 409-426.	0.6	180
322	The cytokines IL-3 and GM-CSF regulate the transcriptional activity of retinoic acid receptors in different in vitro models of myeloid differentiation. <i>Blood</i> , 2002, 99, 746-753.	0.6	34
323	Frequent mutations in the ligand-binding domain of PML-RAR α after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-transretinoic acid and histone deacetylase inhibitors in vitro and in vivo. <i>Blood</i> , 2002, 99, 1356-1363.	0.6	113
324	Interactions of STAT5b-RAR α , a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways. <i>Blood</i> , 2002, 99, 2637-2646.	0.6	89
325	The Stat5-RAR α fusion protein represses transcription and differentiation through interaction with a corepressor complex. <i>Blood</i> , 2002, 99, 2647-2652.	0.6	39
326	Interactions of GATA-2 with the promyelocytic leukemia zinc finger (PLZF) protein, its homologue FAZF, and the t(11;17)-generated PLZF-retinoic acid receptor alpha oncoprotein. <i>Blood</i> , 2002, 99, 3404-3410.	0.6	34
327	IL-3-induced enhancement of retinoic acid receptor activity is mediated through Stat5, which physically associates with retinoic acid receptors in an IL-3-dependent manner. <i>Blood</i> , 2002, 100, 4401-4409.	0.6	47
328	The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. <i>Blood</i> , 2002, 100, 3319-3324.	0.6	70

#	ARTICLE	IF	CITATIONS
329	Response to histone deacetylase inhibition of novel PML/RAR \pm mutants detected in retinoic acid-resistant APL cells. <i>Blood</i> , 2002, 100, 2586-2596.	0.6	63
330	Characterization of the Gene Encoding Mouse Retinoblastoma Binding Protein-7, a Component of Chromatin-Remodeling Complexes. <i>Genomics</i> , 2002, 80, 407-415.	1.3	17
331	Complete remission through blast cell differentiation in PLZF/RAR \pm -positive acute promyelocytic leukemia: in vitro and in vivo studies. <i>Blood</i> , 2002, 100, 1065-1067.	0.6	69
332	Targeted removal of PML-RAR \pm protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia. <i>Blood</i> , 2002, 100, 1008-1013.	0.6	35
333	Structurally Simple Trichostatin A-Like Straight Chain Hydroxamates as Potent Histone Deacetylase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 2877-2885.	2.9	75
334	The Cytotoxicity of Arsenic Trioxide to Normal Hematopoietic Progenitors and Leukemic Cells is Dependent on Their Cell-cycle Status. <i>Leukemia and Lymphoma</i> , 2002, 43, 2191-2199.	0.6	11
335	Anti-Cancer Drugs of Today and Tomorrow: Are we Close to Making the Turn from Treating to Curing Cancer?. <i>Current Pharmaceutical Design</i> , 2002, 8, 1723-1734.	0.9	18
336	Differential gene expression in retinoic acid-induced differentiation of acute promyelocytic leukemia cells, NB4 and HL-60 cells. <i>Biochemical and Biophysical Research Communications</i> , 2002, 296, 1125-1133.	1.0	85
337	Induction of the early-late Ddc gene during Drosophila metamorphosis by the ecdysone receptor. <i>Mechanisms of Development</i> , 2002, 114, 95-107.	1.7	25
338	Plzf Mediates Transcriptional Repression of HoxD Gene Expression through Chromatin Remodeling. <i>Developmental Cell</i> , 2002, 3, 499-510.	3.1	160
339	Methyltransferase Recruitment and DNA Hypermethylation of Target Promoters by an Oncogenic Transcription Factor. <i>Science</i> , 2002, 295, 1079-1082.	6.0	754
340	Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. <i>Blood</i> , 2002, 99, 1014-1022.	0.6	84
341	RAR. , 2002, , 113-140.		0
342	Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. <i>Biochemical Pharmacology</i> , 2002, 64, 1079-1090.	2.0	94
343	Role of MmTRA1b/phospholipid scramblase1 gene expression in the induction of differentiation of human myeloid leukemia cells into granulocytes. <i>Experimental Hematology</i> , 2002, 30, 421-429.	0.2	28
344	A Microplate Reader-Based Nonisotopic Histone Deacetylase Activity Assay. <i>Analytical Biochemistry</i> , 2002, 302, 175-183.	1.1	47
345	A model of transcriptional regulatory networks based on biases in the observed regulation rules. <i>Complexity</i> , 2002, 7, 23-40.	0.9	228
346	New advances in the treatment of acute promyelocytic leukemia. <i>International Journal of Hematology</i> , 2002, 76, 179-187.	0.7	28

#	ARTICLE	IF	CITATIONS
347	The role of retinoids and retinoic acid receptors in normal hematopoiesis. <i>Leukemia</i> , 2002, 16, 1896-1905.	3.3	150
348	Retinoic acid resistance in acute promyelocytic leukemia. <i>Leukemia</i> , 2002, 16, 1940-1958.	3.3	136
349	Variations on a theme: the alternate translocations in APL. <i>Leukemia</i> , 2002, 16, 1927-1932.	3.3	122
350	Spotlight on acute promyelocytic leukemia: controversies and challenges. <i>Leukemia</i> , 2002, 16, 1893-1895.	3.3	0
351	Modelling haematopoietic malignancies in the mouse and therapeutical implications. <i>Oncogene</i> , 2002, 21, 3445-3458.	2.6	45
352	Transcription factor fusions in acute leukemia: variations on a theme. <i>Oncogene</i> , 2002, 21, 3422-3444.	2.6	97
353	Differentiation induction as a treatment for hematologic malignancies. <i>Oncogene</i> , 2002, 21, 3496-3506.	2.6	25
354	How acute promyelocytic leukaemia revived arsenic. <i>Nature Reviews Cancer</i> , 2002, 2, 705-714.	12.8	309
355	Reinventing the Wheel of Cyclic AMP. <i>Annals of the New York Academy of Sciences</i> , 2002, 968, 49-64.	1.8	118
356	Decryption of the retinoid death code in leukemia. <i>Journal of Clinical Immunology</i> , 2002, 22, 117-123.	2.0	9
357	Designed transcription factors as structural, functional and therapeutic probes of chromatin in vivo. <i>EMBO Reports</i> , 2002, 3, 610-615.	2.0	22
358	The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. <i>EMBO Journal</i> , 2003, 22, 3411-3420.	3.5	460
359	C/EBP β : a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells. <i>EMBO Journal</i> , 2003, 22, 5806-5816.	3.5	146
360	The Role of the MLL Gene in Infant Leukemia. <i>International Journal of Hematology</i> , 2003, 78, 390-401.	0.7	36
361	Monitoring PML-RAR α in acute promyelocytic leukemia. <i>Current Oncology Reports</i> , 2003, 5, 391-398.	1.8	7
362	The cell cycle, chromatin and cancer: mechanism-based therapeutics come of age. <i>Drug Discovery Today</i> , 2003, 8, 793-802.	3.2	50
363	Mechanisms involved in the induced differentiation of leukemia cells. , 2003, 100, 257-290.		135
364	The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. <i>BMC Cancer</i> , 2003, 3, 30.	1.1	128

#	ARTICLE	IF	CITATIONS
365	The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. <i>Biochemical Pharmacology</i> , 2003, 66, 1537-1545.	2.0	102
366	A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 3817-3820.	1.0	41
367	The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. <i>Blood Reviews</i> , 2003, 17, 71-97.	2.8	167
368	The role of a Runt domain transcription factor AML1/RUNX1 in leukemogenesis and its clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 45, 129-150.	2.0	68
369	A Fluorogenic Histone Deacetylase Assay Well Suited for High-Throughput Activity Screening. <i>Chemistry and Biology</i> , 2003, 10, 61-68.	6.2	253
370	The history of acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2003, 122, 539-553.	1.2	41
371	C-fms expression correlates with monocytic differentiation in PML-RAR α acute promyelocytic leukemia. <i>Leukemia</i> , 2003, 17, 98-113.	3.3	16
372	Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. <i>Leukemia</i> , 2003, 17, 1454-1463.	3.3	146
373	Retinoid target genes in acute promyelocytic leukemia. <i>Leukemia</i> , 2003, 17, 1723-1730.	3.3	74
375	Fusion proteins of retinoid receptors antagonize TGF- β -induced growth inhibition of lung epithelial cells. <i>Oncogene</i> , 2003, 22, 198-210.	2.6	18
376	Essential role for the dimerization domain of NuMA-RAR α in its oncogenic activities and localization to NuMA sites within the nucleus. <i>Oncogene</i> , 2003, 22, 858-868.	2.6	23
377	CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. <i>Oncogene</i> , 2003, 22, 1002-1011.	2.6	145
378	Regulation of Hoxb2 by APL-associated PLZF protein. <i>Oncogene</i> , 2003, 22, 3685-3697.	2.6	39
379	The cleavage product β -PML α -RAR α contributes to all-trans retinoic acid-mediated differentiation in acute promyelocytic leukemia cells. <i>Oncogene</i> , 2003, 22, 4083-4091.	2.6	16
380	pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor- α in breast cancer. <i>Oncogene</i> , 2003, 22, 3511-3517.	2.6	129
381	VDUP1 upregulated by TGF- β 1 and 1,25-dihydroxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression. <i>Oncogene</i> , 2003, 22, 4035-4046.	2.6	248
382	PSF-TFE3 oncoprotein in papillary renal cell carcinoma inactivates TFE3 and p53 through cytoplasmic sequestration. <i>Oncogene</i> , 2003, 22, 5031-5044.	2.6	38
383	Epigenetic targets in hematopoietic malignancies. <i>Oncogene</i> , 2003, 22, 6489-6496.	2.6	200

#	ARTICLE	IF	CITATIONS
384	Retinoids in cancer therapy and chemoprevention: promise meets resistance. <i>Oncogene</i> , 2003, 22, 7305-7315.	2.6	297
385	Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code. <i>Annals of the New York Academy of Sciences</i> , 2003, 983, 84-100.	1.8	635
386	Indole amide hydroxamic acids as potent inhibitors of histone deacetylases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 1897-1901.	1.0	48
387	Synthesis and Biological Evaluation of 3-(4-Substituted-phenyl)-N-hydroxy-2-propenamides, a New Class of Histone Deacetylase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 5745-5751.	2.9	49
388	Molecular pathogenesis of acute promyelocytic leukaemia and APL variants. <i>Best Practice and Research in Clinical Haematology</i> , 2003, 16, 387-408.	0.7	44
389	Recent progress in the development of assays suited for histone deacetylase inhibitor screening. <i>Molecular Genetics and Metabolism</i> , 2003, 80, 138-147.	0.5	33
390	Retinoids and retinoic acid receptor in cancer. <i>European Journal of Cancer, Supplement</i> , 2003, 1, 13-18.	2.2	7
391	Bcl6-dependent transcriptional repression by BAZF. <i>Biochemical and Biophysical Research Communications</i> , 2003, 303, 600-608.	1.0	24
392	Identification and characterization of two novel human SCAN domain-containing zinc finger genes ZNF396 and ZNF397. <i>Gene</i> , 2003, 310, 193-201.	1.0	14
393	Histone acetylation-mediated regulation of genes in leukaemic cells. <i>European Journal of Cancer</i> , 2003, 39, 1165-1175.	1.3	99
394	Mechanism of SMRT Corepressor Recruitment by the BCL6 BTB Domain. <i>Molecular Cell</i> , 2003, 12, 1551-1564.	4.5	251
395	Apoptotic pathways activated by histone deacetylase inhibitors: implications for the drug-resistant phenotype. <i>Drug Resistance Updates</i> , 2003, 6, 247-256.	6.5	39
396	Differentiation therapy. <i>Current Opinion in Pharmacology</i> , 2003, 3, 338-343.	1.7	100
397	The N-terminal of the estrogen receptor (ER $\hat{\pm}$) mediates transcriptional cross-talk with the retinoic acid receptor in human breast cancer cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2003, 86, 1-14.	1.2	35
398	Vitamin D Analogs in Cancer Prevention and Therapy. <i>Recent Results in Cancer Research</i> , 2003, , .	1.8	9
399	Hematopoiesis and Retinoids: Development and Disease. <i>Leukemia and Lymphoma</i> , 2003, 44, 1881-1891.	0.6	35
400	Modified fatty acids and their possible therapeutic targets in malignant diseases. <i>Expert Opinion on Therapeutic Targets</i> , 2003, 7, 663-677.	1.5	17
401	A Developmentally Regulated Splice Variant from the Complexlola Locus Encoding Multiple Different Zinc Finger Domain Proteins Interacts with the Chromosomal Kinase JIL-1. <i>Journal of Biological Chemistry</i> , 2003, 278, 11696-11704.	1.6	30

#	ARTICLE	IF	CITATIONS
402	Retinoic Acid Receptor $\hat{1}\pm$ Fusion to PML Affects Its Transcriptional and Chromatin-Remodeling Properties. <i>Molecular and Cellular Biology</i> , 2003, 23, 8795-8808.	1.1	36
403	Isotype-Restricted Corepressor Recruitment: a Constitutively Closed Helix 12 Conformation in Retinoic Acid Receptors $\hat{1}^2$ and $\hat{1}^3$ Interferes with Corepressor Recruitment and Prevents Transcriptional Repression. <i>Molecular and Cellular Biology</i> , 2003, 23, 2844-2858.	1.1	58
404	Growth Suppression by Acute Promyelocytic Leukemia-Associated Protein PLZF Is Mediated by Repression of c-myc Expression. <i>Molecular and Cellular Biology</i> , 2003, 23, 9375-9388.	1.1	120
405	Proteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZF. <i>Journal of Cell Biology</i> , 2003, 163, 489-502.	2.3	147
407	Fusion Protein of Retinoic Acid Receptor $\hat{1}\pm$ with Promyelocytic Leukemia Protein or Promyelocytic Leukemia Zinc Finger Protein Recruits N-CoR-TBLR1 Corepressor Complex to Repress Transcription in Vivo. <i>Journal of Biological Chemistry</i> , 2003, 278, 30788-30795.	1.6	43
408	Tip60 Is a Co-repressor for STAT3. <i>Journal of Biological Chemistry</i> , 2003, 278, 11197-11204.	1.6	94
409	MICoA, a Novel Metastasis-associated Protein 1 (MTA1) Interacting Protein Coactivator, Regulates Estrogen Receptor- $\hat{1}\pm$ Transactivation Functions. <i>Journal of Biological Chemistry</i> , 2003, 278, 19209-19219.	1.6	62
410	The inv(16) Fusion Protein Associates with Corepressors via a Smooth Muscle Myosin Heavy-Chain Domain. <i>Molecular and Cellular Biology</i> , 2003, 23, 607-619.	1.1	148
411	A further case of acute myelomonocytic leukemia with inv(8) chromosomal rearrangement and MOZ-NCOA2 gene fusion. <i>International Journal of Molecular Medicine</i> , 2003, 12, 423.	1.8	5
412	Nuclear receptor superfamily: Principles of signaling. <i>Pure and Applied Chemistry</i> , 2003, 75, 1619-1664.	0.9	41
413	Hormonal and Differentiation Agents in Cancer Growth Suppression. , 2003, 223, 505-522.		3
414	From Discovery to the Coming Generation of Histone Deacetylase Inhibitors. <i>Current Medicinal Chemistry</i> , 2003, 10, 2351-2358.	1.2	121
415	Short-Chain Fatty Acid Inhibitors of Histone Deacetylases: Promising Anticancer Therapeutics?. <i>Current Cancer Drug Targets</i> , 2003, 3, 219-236.	0.8	132
416	Determination of Nuclear Receptor Corepressor Interactions with the Thyroid Hormone Receptor. <i>Molecular Endocrinology</i> , 2003, 17, 273-286.	3.7	72
417	PLZF is a negative regulator of retinoic acid receptor transcriptional activity. <i>Nuclear Receptor</i> , 2003, 1, 6.	10.0	36
418	Molecular sequelae of histone deacetylase inhibition in human malignant B cells. <i>Blood</i> , 2003, 101, 4055-4062.	0.6	296
419	Comparative analysis of genes regulated by PML/RAR $\hat{1}\pm$ and PLZF/RAR $\hat{1}\pm$ in response to retinoic acid using oligonucleotide arrays. <i>Blood</i> , 2003, 102, 3727-3736.	0.6	89
420	Retinoid Receptors. , 2003, , 298-311.		1

#	ARTICLE	IF	CITATIONS
421	Targeted Histone Deacetylase Inhibition for Cancer Therapy. <i>Current Cancer Drug Targets</i> , 2004, 4, 205-218.	0.8	82
422	Nuclear Receptor Recruitment of Histone-Modifying Enzymes to Target Gene Promoters. <i>Vitamins and Hormones</i> , 2004, 68, 93-122.	0.7	44
423	Retinoids and TRAIL: Two Cooperating Actors to Fight Against Cancer. <i>Vitamins and Hormones</i> , 2004, 67, 319-345.	0.7	18
424	Remodeling Chromatin in the Biology and Treatment of Acute Leukemia. <i>Cancer Reviews: Asia-Pacific</i> , 2004, 02, 109-118.	0.1	0
425	Tyrosine Agonists Reverse the Molecular Defects Associated with Dominant-Negative Mutations in Human Peroxisome Proliferator-Activated Receptor β . <i>Endocrinology</i> , 2004, 145, 1527-1538.	1.4	55
427	PML β -RARA-RXR Oligomers Mediate Retinoid and Rexinoid/cAMP Cross-Talk in Acute Promyelocytic Leukemia Cell Differentiation. <i>Journal of Experimental Medicine</i> , 2004, 199, 1163-1174.	4.2	148
428	Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 540-545.	3.3	533
429	Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells. <i>Cancer Research</i> , 2004, 64, 2580-2589.	0.4	215
430	Leukemia/Lymphoma-related Factor, a POZ Domain-containing Transcriptional Repressor, Interacts with Histone Deacetylase-1 and Inhibits Cartilage Oligomeric Matrix Protein Gene Expression and Chondrogenesis. <i>Journal of Biological Chemistry</i> , 2004, 279, 47081-47091.	1.6	88
431	Metastasis-Associated Protein 1 Interacts with NRIF3, an Estrogen-Inducible Nuclear Receptor Coregulator. <i>Molecular and Cellular Biology</i> , 2004, 24, 6581-6591.	1.1	45
432	PLASMA PHARMACOKINETICS AND METABOLISM OF THE HISTONE DEACETYLASE INHIBITOR TRICHOSTATIN A AFTER INTRAPERITONEAL ADMINISTRATION TO MICE. <i>Drug Metabolism and Disposition</i> , 2004, 32, 1132-1138.	1.7	79
433	All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 5328-5335.	3.3	564
434	Epigenomic Changes during Leukemia Cell Differentiation: Analysis of Histone Acetylation and Cytosine Methylation Using CpG Island Microarrays. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 311, 968-981.	1.3	74
435	Retinoids: potential in cancer prevention and therapy. <i>Expert Reviews in Molecular Medicine</i> , 2004, 6, 1-23.	1.6	90
436	Involvement of UBE1L in ISG15 Conjugation during Retinoid-induced Differentiation of Acute Promyelocytic Leukemia. <i>Journal of Biological Chemistry</i> , 2004, 279, 18178-18187.	1.6	65
437	Repression by TTK69 of GAGA-mediated Activation Occurs in the Absence of TTK69 Binding to DNA and Solely Requires the Contribution of the POZ/BTB Domain of TTK69. <i>Journal of Biological Chemistry</i> , 2004, 279, 9725-9732.	1.6	18
438	Tax Relieves Transcriptional Repression by Promoting Histone Deacetylase 1 Release from the Human T-Cell Leukemia Virus Type 1 Long Terminal Repeat. <i>Journal of Virology</i> , 2004, 78, 6735-6743.	1.5	48
439	A Review of Depsipeptide and Other Histone Deacetylase Inhibitors in Clinical Trials. <i>Current Pharmaceutical Design</i> , 2004, 10, 2289-2298.	0.9	185

#	ARTICLE	IF	CITATIONS
440	Role of histone deacetylase inhibitors in the treatment of cancer (Review). <i>International Journal of Oncology</i> , 2004, 25, 1509.	1.4	32
441	Molecular cloning and characterization of a novel human BTBD8 gene containing double BTB/POZ domains. <i>International Journal of Molecular Medicine</i> , 2004, 13, 193.	1.8	2
442	The promyelocytic leukemia zinc finger protein down-regulates apoptosis and expression of the proapoptotic BID protein in lymphocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 1898-1903.	3.3	41
443	The Fusion Oncoprotein PML-RAR α Induces Endoplasmic Reticulum (ER)-associated Degradation of N-CoR and ER Stress. <i>Journal of Biological Chemistry</i> , 2004, 279, 11814-11824.	1.6	52
444	BLADE-ON-PETIOLE1 Encodes a BTB/POZ Domain Protein Required for Leaf Morphogenesis in <i>Arabidopsis thaliana</i> . <i>Plant and Cell Physiology</i> , 2004, 45, 1361-1370.	1.5	165
445	High-throughput screening of genome fragments bound to differentially acetylated histones. <i>Genes To Cells</i> , 2004, 9, 1167-1174.	0.5	10
446	Plzf is required in adult male germ cells for stem cell self-renewal. <i>Nature Genetics</i> , 2004, 36, 647-652.	9.4	791
447	Rapid induction of cAMP/PKA pathway during retinoic acid-induced acute promyelocytic leukemia cell differentiation. <i>Leukemia</i> , 2004, 18, 285-292.	3.3	79
448	Acute promyelocytic leukemia: where does it stem from?. <i>Leukemia</i> , 2004, 18, 375-384.	3.3	88
449	Acute promyelocytic leukemia: PML/RAR α and the leukemic stem cell. <i>Leukemia</i> , 2004, 18, 1169-1175.	3.3	77
450	Plakoglobin is a new target gene of histone deacetylase in human fibrosarcoma HT1080 cells. <i>Oncogene</i> , 2004, 23, 1704-1711.	2.6	22
451	Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells. <i>Oncogene</i> , 2004, 23, 6712-6725.	2.6	130
452	Silencing of androgen-regulated genes using a fusion of AR with the PLZF transcriptional repressor. <i>Oncogene</i> , 2004, 23, 7561-7570.	2.6	9
453	HDAC4 mediates transcriptional repression by the acute promyelocytic leukaemia-associated protein PLZF. <i>Oncogene</i> , 2004, 23, 8777-8784.	2.6	69
454	SYT, a partner of SYT-SSX oncoprotein in synovial sarcomas, interacts with mSin3A, a component of histone deacetylase complex. <i>Laboratory Investigation</i> , 2004, 84, 1484-1490.	1.7	43
455	Targeted therapies in myeloid leukemia. <i>Seminars in Cancer Biology</i> , 2004, 14, 41-62.	4.3	45
456	Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2004, 127, 1078-1086.	0.4	71
457	All-trans retinoic acid directly up-regulates thrombopoietin transcription in human bone marrow stromal cells. <i>Experimental Hematology</i> , 2004, 32, 45-51.	0.2	10

#	ARTICLE	IF	CITATIONS
458	Mechanisms responsible for regulation of pyruvate dehydrogenase kinase 4 gene expression. <i>Advances in Enzyme Regulation</i> , 2004, 44, 109-121.	2.9	61
459	Acetylation of proteins as novel target for antitumor therapy: Review article. <i>Amino Acids</i> , 2004, 26, 435-41.	1.2	77
460	Isolation from Cochlea of a Novel Human Intronless Gene with Predominant Fetal Expression. <i>JARO - Journal of the Association for Research in Otolaryngology</i> , 2004, 5, 185-202.	0.9	48
461	Estrogen receptor enhances the antiproliferative effects of trichostatin A and HC-toxin in human breast cancer cells. <i>Archives of Pharmacal Research</i> , 2004, 27, 554-561.	2.7	8
462	Antiproliferative effect of trichostatin a and hc-toxin in T47D Human breast cancer cells. <i>Archives of Pharmacal Research</i> , 2004, 27, 640-645.	2.7	24
463	(2-Amino-phenyl)-amides of α -substituted alkanolic acids as new histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 283-287.	1.0	29
464	Induction of differentiation of retinoic acid-resistant acute promyelocytic leukemia cells by the combination of all-trans retinoic acid and granulocyte colony-stimulating factor. <i>Leukemia Research</i> , 2004, 28, 525-532.	0.4	21
465	The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. <i>Leukemia Research</i> , 2004, 28, 891-900.	0.4	161
466	A Closer Look at Specific Therapeutic Strategies in Leukemia. <i>Leukemia and Lymphoma</i> , 2004, 45, 1767-1773.	0.6	2
467	Epigenetics and Cancer. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2004, 41, 585-607.	2.7	54
468	The PML-RAR α Fusion Protein and Targeted Therapy for Acute Promyelocytic Leukemia. <i>Leukemia and Lymphoma</i> , 2004, 45, 639-648.	0.6	39
469	GMPOZ, a BTB/POZ Domain Nuclear Protein, is a Regulator of Hormone Responsive Gene Expression in Barley Aleurone. <i>Plant and Cell Physiology</i> , 2004, 45, 945-950.	1.5	12
470	Inhibitors of histone deacetylases promote hematopoietic stem cell self-renewal. <i>Cytotherapy</i> , 2004, 6, 328-336.	0.3	62
471	The Role of Corepressors in Transcriptional Regulation by Nuclear Hormone Receptors. <i>Annual Review of Physiology</i> , 2004, 66, 315-360.	5.6	289
472	Histone modification enzymes: novel targets for cancer drugs. <i>Expert Opinion on Emerging Drugs</i> , 2004, 9, 135-154.	1.0	70
474	β -Catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells. <i>Blood</i> , 2004, 103, 3535-3543.	0.6	88
475	Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 387-400.	1.1	6
476	Histone deacetylase inhibitors – a new tool to treat cancer. <i>Cancer Treatment Reviews</i> , 2004, 30, 461-472.	3.4	97

#	ARTICLE	IF	CITATIONS
477	Dual intracellular signaling by proteolytic cleavage of membrane-anchored heparin-binding EGF-like growth factor. <i>Cytokine and Growth Factor Reviews</i> , 2004, 15, 13-19.	3.2	54
478	Differential protein acetylation induced by novel histone deacetylase inhibitors. <i>Biochemical and Biophysical Research Communications</i> , 2004, 325, 683-690.	1.0	60
479	Expression and functional characterization of recombinant human HDAC1 and HDAC3. <i>Life Sciences</i> , 2004, 74, 2693-2705.	2.0	38
480	RETINOIC ACID RECEPTORS AND CANCERS. <i>Annual Review of Nutrition</i> , 2004, 24, 201-221.	4.3	245
481	Expression of SMRT ² promotes ligand-induced activation of mutated and wild-type retinoid receptors. <i>Blood</i> , 2004, 104, 4226-4235.	0.6	9
482	Combination of retinoic acid and tumor necrosis factor overcomes the maturation block in a variety of retinoic acid-resistant acute promyelocytic leukemia cells. <i>Blood</i> , 2004, 104, 3335-3342.	0.6	25
483	Dimerization: a versatile switch for oncogenesis. <i>Blood</i> , 2004, 104, 919-922.	0.6	68
484	Chromatin Remodeling and Cancer. , 2004, , 265-295.		2
486	Leukemia Cells and the Cytokine Network: Therapeutic Prospects. <i>Experimental Biology and Medicine</i> , 2004, 229, 121-137.	1.1	8
487	Benzodithiophenes Induce Differentiation and Apoptosis in Human Leukemia Cells. <i>Cancer Research</i> , 2005, 65, 7847-7855.	0.4	9
488	Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies. <i>Current Opinion in Hematology</i> , 2005, 12, 1-6.	1.2	74
490	Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells. <i>Blood</i> , 2005, 105, 1669-1677.	0.6	46
491	Retinoids and myelomonocytic growth factors cooperatively activate RAR β and induce human myeloid leukemia cell differentiation via MAP kinase pathways. <i>Blood</i> , 2005, 105, 341-349.	0.6	68
492	ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2005, 1751, 110-117.	1.1	141
493	Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. <i>Journal of Neurochemistry</i> , 2005, 93, 992-999.	2.1	111
494	Identification of a novel BTB-zinc finger transcriptional repressor, CIBZ, that interacts with CtBP corepressor. <i>Genes To Cells</i> , 2005, 10, 871-885.	0.5	42
495	How patients have benefited from mouse models of acute promyelocytic leukaemia. <i>Nature Reviews Cancer</i> , 2005, 5, 821-827.	12.8	36
496	Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. <i>Cell Death and Differentiation</i> , 2005, 12, 395-404.	5.0	301

#	ARTICLE	IF	CITATIONS
497	Dynamic and reversibility of heterochromatic gene silencing in human disease. <i>Cell Research</i> , 2005, 15, 679-690.	5.7	32
498	Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells. <i>EMBO Journal</i> , 2005, 24, 1232-1242.	3.5	38
499	The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells. <i>Leukemia</i> , 2005, 19, 1161-1168.	3.3	61
500	Predicting the effect of transcription therapy in hematologic malignancies. <i>Leukemia</i> , 2005, 19, 1109-1117.	3.3	17
501	Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML. <i>Leukemia</i> , 2005, 19, 1719-1728.	3.3	19
502	p53 in human embryonal carcinoma: identification of a transferable, transcriptional repression domain in the N-terminal region of p53. <i>Oncogene</i> , 2005, 24, 1481-1490.	2.6	14
503	Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo. <i>Oncogene</i> , 2005, 24, 1820-1830.	2.6	83
504	Mayven induces c-Jun expression and cyclin D1 activation in breast cancer cells. <i>Oncogene</i> , 2005, 24, 2398-2409.	2.6	19
505	HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. <i>Oncogene</i> , 2005, 24, 4609-4623.	2.6	178
506	A sumoylation site in PML/RARA is essential for leukemic transformation. <i>Cancer Cell</i> , 2005, 7, 143-153.	7.7	139
507	Histone deacetylase inhibitors and cancer: from cell biology to the clinic. <i>European Journal of Cell Biology</i> , 2005, 84, 109-121.	1.6	111
508	Genome-wide analysis of HDAC function. <i>Trends in Genetics</i> , 2005, 21, 608-615.	2.9	111
509	Histone Deacetylase Inhibitors: Emerging Anticancer Therapeutic Agents?. <i>Clinical Lung Cancer</i> , 2005, 7, S19-S30.	1.1	23
510	Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228). <i>Journal of Cellular Physiology</i> , 2005, 203, 387-397.	2.0	42
511	Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors. <i>International Journal of Cancer</i> , 2005, 116, 784-792.	2.3	96
512	Cloning of two rat PDIP1 related genes and their interactions with proliferating cell nuclear antigen. <i>Journal of Experimental Zoology Part A, Comparative Experimental Biology</i> , 2005, 303A, 227-240.	1.3	35
513	Induction of murine leukemia and lymphoma by dominant negative retinoic acid receptor $\hat{\pm}$. <i>Molecular Carcinogenesis</i> , 2005, 44, 252-261.	1.3	6
514	The molecular pathogenesis of acute myeloid leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 56, 195-221.	2.0	63

#	ARTICLE	IF	CITATIONS
515	Synergistic apoptosis induction by proteasome and histone deacetylase inhibitors is dependent on protein synthesis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2005, 10, 743-758.	2.2	13
516	The BTB Domain Zinc Finger Proteins. , 2005, , 134-150.		2
517	Remodeling Chromatin and Stress Resistance in the Central Nervous System: Histone Deacetylase Inhibitors as Novel and Broadly Effective Neuroprotective Agents. <i>CNS and Neurological Disorders</i> , 2005, 4, 41-50.	4.3	142
518	A Mechanistic Approach to Anticancer Therapy: Targeting the Cell Cycle with Histone Deacetylase Inhibitors. <i>Current Pharmaceutical Design</i> , 2005, 11, 1091-1104.	0.9	60
519	ASB2 Is an Elongin BC-interacting Protein That Can Assemble with Cullin 5 and Rbx1 to Reconstitute an E3 Ubiquitin Ligase Complex. <i>Journal of Biological Chemistry</i> , 2005, 280, 5468-5474.	1.6	64
520	The BLADE ON PETIOLE genes act redundantly to control the growth and development of lateral organs. <i>Development (Cambridge)</i> , 2005, 132, 2203-2213.	1.2	207
521	Histone Acetyltransferase Activity of p300 Is Required for Transcriptional Repression by the Promyelocytic Leukemia Zinc Finger Protein. <i>Molecular and Cellular Biology</i> , 2005, 25, 5552-5566.	1.1	99
522	Benzodithiophenes Potentiate Differentiation of Acute Promyelocytic Leukemia Cells by Lowering the Threshold for Ligand-Mediated Corepressor/Coactivator Exchange with Retinoic Acid Receptor β and Enhancing Changes in all-trans-Retinoic Acid-Regulated Gene Expression. <i>Cancer Research</i> , 2005, 65, 7856-7865.	0.4	11
523	The Clinical Relevance of Steroid Hormone Receptor Corepressors: Table 1.. <i>Clinical Cancer Research</i> , 2005, 11, 2822-2831.	3.2	36
524	Interplay of RUNX1/MTG8 and DNA Methyltransferase 1 in Acute Myeloid Leukemia. <i>Cancer Research</i> , 2005, 65, 1277-1284.	0.4	133
525	Alteration of SMRT Tumor Suppressor Function in Transformed Non-Hodgkin Lymphomas. <i>Cancer Research</i> , 2005, 65, 4554-4561.	0.4	22
526	Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor- β and the transcriptional repressor PLZF. <i>Gene Therapy</i> , 2005, 12, 452-460.	2.3	16
527	The Nuclear Receptor Corepressor Deacetylase Activating Domain Is Essential for Repression by Thyroid Hormone Receptor. <i>Molecular Endocrinology</i> , 2005, 19, 1443-1451.	3.7	39
528	Leukemia-Associated Fusion Proteins: Multiple Mechanisms of Action to Drive Cell Transformation. <i>Cell Cycle</i> , 2005, 4, 67-69.	1.3	17
529	Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4. <i>Genes and Development</i> , 2005, 19, 827-839.	2.7	193
530	Artificial Zinc Finger Fusions Targeting Sp1-binding Sites and the trans-Activator-responsive Element Potently Repress Transcription and Replication of HIV-1. <i>Journal of Biological Chemistry</i> , 2005, 280, 21545-21552.	1.6	20
531	Histone Deacetylase-1 Represses Transcription by Interacting with Zinc-Fingers and Interfering with the DNA Binding Activity of Sp1. <i>Cellular Physiology and Biochemistry</i> , 2005, 16, 23-30.	1.1	18
532	The BTB domain of the nuclear matrix protein NRP/B is required for neurite outgrowth. <i>Journal of Cell Science</i> , 2005, 118, 5537-5548.	1.2	18

#	ARTICLE	IF	CITATIONS
533	Repression of an Interleukin-4-responsive Promoter Requires Cooperative BCL-6 Function. <i>Journal of Biological Chemistry</i> , 2005, 280, 13114-13121.	1.6	40
534	Cullins 3a and 3b Assemble with Members of the Broad Complex/Tramtrack/Bric-a-Brac (BTB) Protein Family to Form Essential Ubiquitin-Protein Ligases (E3s) in <i>Arabidopsis</i> *. <i>Journal of Biological Chemistry</i> , 2005, 280, 18810-18821.	1.6	142
535	PRAM-1 Potentiates Arsenic Trioxide-induced JNK Activation. <i>Journal of Biological Chemistry</i> , 2005, 280, 9043-9048.	1.6	8
536	Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: Involvement of both death receptor and mitochondrial pathways. <i>International Journal of Molecular Medicine</i> , 2005, 16, 1125.	1.8	30
537	Mxi1 isoforms are expressed in hematological cell lines and normal bone marrow. <i>International Journal of Oncology</i> , 2005, 26, 1369.	1.4	3
538	TRAIL: At the Center of Drugable Anti-Tumor Pathways. <i>Cell Cycle</i> , 2005, 4, 914-918.	1.3	13
539	Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. <i>Nature</i> , 2005, 433, 278-285.	13.7	461
540	The Theoretical Basis of Transcriptional Therapy of Cancer: Can It Be Put Into Practice?. <i>Journal of Clinical Oncology</i> , 2005, 23, 3957-3970.	0.8	31
541	Crystal Structure of a Bacterial Class 2 Histone Deacetylase Homologue. <i>Journal of Molecular Biology</i> , 2005, 354, 107-120.	2.0	151
542	The Human Tumor Antigen PRAME Is a Dominant Repressor of Retinoic Acid Receptor Signaling. <i>Cell</i> , 2005, 122, 835-847.	13.5	363
543	Tumor Suppressor HIC1 Directly Regulates SIRT1 to Modulate p53-Dependent DNA-Damage Responses. <i>Cell</i> , 2005, 123, 437-448.	13.5	591
544	Kaiso/p120-Catenin and TCF/β-Catenin Complexes Coordinately Regulate Canonical Wnt Gene Targets. <i>Developmental Cell</i> , 2005, 8, 843-854.	3.1	206
545	Acute myeloid leukemia: Therapeutic impact of epigenetic drugs. <i>International Journal of Biochemistry and Cell Biology</i> , 2005, 37, 1752-1762.	1.2	47
546	Epigenetics of cervical cancer. An overview and therapeutic perspectives. <i>Molecular Cancer</i> , 2005, 4, 38.	7.9	183
549	Histone Deacetylase Inhibitors in Cancer Therapy. <i>Cancer Investigation</i> , 2006, 24, 521-527.	0.6	44
550	Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2203-2210.	1.9	141
551	The methyl-CpG binding protein MBD1 is required for PML-RAR α function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 1400-1405.	3.3	93
552	Establishment and Maintenance of DNA Methylation Patterns in Mammals. , 2006, 301, 179-201.		141

#	ARTICLE	IF	CITATIONS
553	Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RAR \pm as a component of the N-CoR co-repressor complex to repress transcription in vivo. <i>Biochemical and Biophysical Research Communications</i> , 2006, 345, 1471-1480.	1.0	48
554	Histone deacetylase inhibitors: Multifunctional anticancer agents. <i>Cancer Treatment Reviews</i> , 2006, 32, 157-165.	3.4	212
555	Evidence of recurrent gene fusions in common epithelial tumors. <i>Trends in Molecular Medicine</i> , 2006, 12, 529-536.	3.5	35
556	Histone lysine trimethylation exhibits a distinct perinuclear distribution in Plzf-expressing spermatogonia. <i>Developmental Biology</i> , 2006, 293, 461-472.	0.9	90
557	Differentiation Induction in Leukemia and Lymphoma. , 2006, , 491-506.		3
558	Molecular genetics of acute lymphoblastic leukemia. , 2006, , 272-297.		0
560	Molecular genetics of acute myeloid leukemia. , 2006, , 298-338.		0
561	Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. <i>Blood</i> , 2006, 107, 1546-1554.	0.6	92
562	Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia. <i>Blood</i> , 2006, 107, 698-707.	0.6	48
563	ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. <i>Blood</i> , 2006, 107, 3330-3338.	0.6	186
564	Review: Recent Clinical Trials in Epigenetic Therapy. <i>Reviews on Recent Clinical Trials</i> , 2006, 1, 169-182.	0.4	54
565	Effect of all-trans retinoic acid and sodium butyrate in vitro and in vivo on thyroid carcinoma xenografts. <i>Anti-Cancer Drugs</i> , 2006, 17, 559-563.	0.7	6
566	HDAC Inhibitors. , 2006, , 315-332.		4
567	Limited proteolysis of human histone deacetylase 1. <i>BMC Biochemistry</i> , 2006, 7, 22.	4.4	7
568	Histone Deacetylase Inhibitors Induce Apoptosis with Minimal Viral Reactivation in Cells Infected with Kaposi's Sarcoma-Associated Herpesvirus. <i>Journal of Investigative Dermatology</i> , 2006, 126, 2516-2524.	0.3	10
569	Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. <i>Leukemia</i> , 2006, 20, 212-217.	3.3	111
570	Histone deacetylase inhibitor FK228 suppresses the Ras \rightarrow MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma. <i>Oncogene</i> , 2006, 25, 512-524.	2.6	53
571	Pro-proliferative function of the long isoform of PML-RAR \pm involved in acute promyelocytic leukemia. <i>Oncogene</i> , 2006, 25, 3375-3386.	2.6	15

#	ARTICLE	IF	CITATIONS
572	Depsipeptide-resistant KU812 cells show reversible P-glycoprotein expression, hyper-acetylated histones, and modulated gene expression profile. <i>Leukemia Research</i> , 2006, 30, 723-734.	0.4	39
573	Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention?. <i>Carcinogenesis</i> , 2006, 27, 344-349.	1.3	179
574	Effects of Histone Deacetylase Inhibitors, Sodium Phenyl Butyrate and Vitamin B3, in Combination with Retinoic Acid on Granulocytic Differentiation of Human Promyelocytic Leukemia HL-60 Cells. <i>Annals of the New York Academy of Sciences</i> , 2006, 1091, 356-367.	1.8	29
575	PML-RAR α and AML1-ETO translocations are rarely associated with methylation of the RAR α 2 promoter. <i>Annals of Hematology</i> , 2006, 85, 689-704.	0.8	19
576	Abnormal histone acetylase and deacetylase expression and function in lung inflammation. <i>Inflammation Research</i> , 2006, 55, 311-321.	1.6	35
577	Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: Novel classes of histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 4048-4052.	1.0	34
578	Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. <i>European Journal of Haematology</i> , 2006, 76, 42-50.	1.1	80
579	Epigenetic heterochromatin markers distinguish terminally differentiated leukocytes from incompletely differentiated leukemia cells in human blood. <i>Experimental Hematology</i> , 2006, 34, 453-462.	0.2	36
580	Forced retinoic acid receptor α homodimers prime mice for APL-like leukemia. <i>Cancer Cell</i> , 2006, 9, 81-94.	7.7	82
581	Forced homo-oligomerization of RAR α leads to transformation of primary hematopoietic cells. <i>Cancer Cell</i> , 2006, 9, 95-108.	7.7	67
582	Retinoic acids and trichostatin A (TSA), a histone deacetylase inhibitor, induce human pyruvate dehydrogenase kinase 4 (PDK4) gene expression. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 2006, 1759, 141-151.	2.4	37
583	POZ for effect α POZ-ZF transcription factors in cancer and development. <i>Trends in Cell Biology</i> , 2006, 16, 578-587.	3.6	225
584	Born to bind: the BTB protein α protein interaction domain. <i>BioEssays</i> , 2006, 28, 1194-1202.	1.2	223
585	Histone Deacetylases as Targets for Dietary Cancer Preventive Agents: Lessons Learned with Butyrate, Diallyl Disulfide, and Sulforaphane. <i>Current Drug Targets</i> , 2006, 7, 443-452.	1.0	158
586	PAX8-Peroxisome Proliferator-Activated Receptor γ (PPAR γ) Disrupts Normal PAX8 or PPAR γ Transcriptional Function and Stimulates Follicular Thyroid Cell Growth. <i>Endocrinology</i> , 2006, 147, 367-376.	1.4	60
587	Chromatin Modifications (Acetylation/ Deacetylation/ Methylation) As New Targets for HIV Therapy. <i>Current Pharmaceutical Design</i> , 2006, 12, 1975-1993.	0.9	27
588	Knowledge of Epigenetic Influence for Prostate Cancer Therapy. <i>Current Cancer Drug Targets</i> , 2006, 6, 533-551.	0.8	7
589	Arsenic Trioxide in Hematological Malignancies: The New Discovery of an Ancient Drug. <i>Current Pharmaceutical Biotechnology</i> , 2006, 7, 397-405.	0.9	41

#	ARTICLE	IF	CITATIONS
590	Histone Deacetylase Enzymes as Potential Drug Targets in Cancer and Parasitic Diseases. <i>Journal of Biomedicine and Biotechnology</i> , 2006, 2006, 1-10.	3.0	35
591	Cleavage of Misfolded Nuclear Receptor Corepressor Confers Resistance to Unfolded Protein Response-Induced Apoptosis. <i>Cancer Research</i> , 2006, 66, 9903-9912.	0.4	19
592	Sequential Valproic Acid/All-trans Retinoic Acid Treatment Reprograms Differentiation in Refractory and High-Risk Acute Myeloid Leukemia. <i>Cancer Research</i> , 2006, 66, 8903-8911.	0.4	125
593	Monocytic leukemia zinc finger protein is essential for the development of long-term reconstituting hematopoietic stem cells. <i>Genes and Development</i> , 2006, 20, 1175-1186.	2.7	148
594	Dimerization-induced corepressor binding and relaxed DNA-binding specificity are critical for PML/RARA-induced immortalization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 9238-9243.	3.3	59
595	The Corepressor Silencing Mediator for Retinoid and Thyroid Hormone Receptor Facilitates Cellular Recovery from DNA Double-Strand Breaks. <i>Cancer Research</i> , 2006, 66, 9316-9322.	0.4	23
596	Histone Deacetylase Inhibitor Depsipeptide (FK228) Induces Apoptosis in Leukemic Cells by Facilitating Mitochondrial Translocation of Bax, Which Is Enhanced by the Proteasome Inhibitor Bortezomib. <i>Acta Haematologica</i> , 2006, 115, 78-90.	0.7	48
597	Histone Deacetylase 8 Safeguards the Human Ever-Shorter Telomeres 1B (hEST1B) Protein from Ubiquitin-Mediated Degradation. <i>Molecular and Cellular Biology</i> , 2006, 26, 5259-5269.	1.1	78
598	Cytoplasmic Function of Mutant Promyelocytic Leukemia (PML) and PML-Retinoic Acid Receptor-1. <i>Journal of Biological Chemistry</i> , 2006, 281, 14465-14473.	1.6	27
599	In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR1 blockade in the pathogenesis of acute promyelocytic leukemia. <i>Journal of Experimental Medicine</i> , 2006, 203, 821-828.	4.2	42
600	Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1248-1255.	1.9	65
601	Knockdown of XAB2 Enhances All-Trans Retinoic Acid-Induced Cellular Differentiation in All-Trans Retinoic Acid-Sensitive and -Resistant Cancer Cells. <i>Cancer Research</i> , 2007, 67, 1019-1029.	0.4	23
602	PPARgamma-Active triterpenoid CDDO enhances ATRA-induced differentiation in APL. <i>Cancer Biology and Therapy</i> , 2007, 6, 1967-1977.	1.5	33
603	Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2967-2975.	1.9	70
604	Retinoic acid modulates chromatin to potentiate tumor necrosis factor alpha signaling on the DIF2 promoter. <i>Nucleic Acids Research</i> , 2007, 36, 435-443.	6.5	14
605	Therapeutic targeting of nuclear receptor corepressor misfolding in acute promyelocytic leukemia cells with genistein. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2240-2248.	1.9	27
606	Aberrant Chromatin Remodeling by Retinoic Acid Receptor 1 Fusion Proteins Assessed at the Single-Cell Level. <i>Molecular Biology of the Cell</i> , 2007, 18, 3941-3951.	0.9	15
607	To Be, or Not To Be: That is the Question-Lineage Commitment in Hematopoiesis. <i>Current Immunology Reviews</i> , 2007, 3, 258-268.	1.2	0

#	ARTICLE	IF	CITATIONS
608	Adhesion molecules and differentiation syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia. <i>Haematologica</i> , 2007, 92, 1615-1622.	1.7	39
609	In Vitro Phase I Cytochrome P450 Metabolism, Permeability and Pharmacokinetics of SB639, a Novel Histone Deacetylase Inhibitor in Preclinical Species. <i>Biological and Pharmaceutical Bulletin</i> , 2007, 30, 1021-1024.	0.6	26
610	Histone deacetylase inhibitors suppress IFN α -induced up-regulation of promyelocytic leukemia protein. <i>Blood</i> , 2007, 109, 1373-1380.	0.6	40
611	Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. <i>Blood</i> , 2007, 109, 2781-2790.	0.6	279
612	Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia. <i>Blood</i> , 2007, 109, 4432-4440.	0.6	82
613	Histone Deacetylase Inhibitors and Demethylating Agents: Clinical Development of Histone Deacetylase Inhibitors for Cancer Therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2007, 13, 30-39.	1.0	46
614	Histone Deacetylase Inhibitors: Biology and Mechanism of Action. <i>Cancer Journal (Sudbury, Mass)</i> , 2007, 13, 23-29.	1.0	96
615	Targeting Transcription Factors in Acute Leukemia in Children. <i>Current Drug Targets</i> , 2007, 8, 727-737.	1.0	18
616	SUMO modification modulates the transrepression activity of PLZF. <i>Biochemical and Biophysical Research Communications</i> , 2007, 358, 475-482.	1.0	19
617	MS-275, a potent orally available inhibitor of histone deacetylases—The development of an anticancer agent. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 1388-1405.	1.2	134
619	RAR α -PLZF overcomes PLZF-mediated repression of <i>CRABPI</i> , contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 18694-18699.	3.3	62
620	Acute Myelogenous Leukemia. , 2007, , .		0
621	Mutant Transcription Factors and Tyrosine Kinases as Therapeutic Targets for Leukemias: From Acute Promyelocytic Leukemia to Chronic Myeloid Leukemia and Beyond. <i>Advances in Cancer Research</i> , 2007, 98, 191-220.	1.9	6
622	Preclinical Studies of Novel Targeted Therapies. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 1071-1091.	0.9	19
623	Physical and Functional Interactions of Human Endogenous Retrovirus Proteins Np9 and Rec with the Promyelocytic Leukemia Zinc Finger Protein. <i>Journal of Virology</i> , 2007, 81, 5607-5616.	1.5	121
624	Histone deacetylase inhibitors in cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 659-678.	1.9	193
625	Treatment of relapsed or refractory acute promyelocytic leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 57-65.	0.7	92
626	Development of histone deacetylase inhibitors for cancer treatment. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 583-598.	1.1	141

#	ARTICLE	IF	CITATIONS
627	Development and validation of high-performance liquid chromatography-tandem mass spectrometry assay for 6-(3-benzoyl-ureido)-hexanoic acid hydroxyamide, a novel HDAC inhibitor, in mouse plasma for pharmacokinetic studies. <i>Biomedical Chromatography</i> , 2007, 21, 184-189.	0.8	32
628	KN-62 analogues as potent differentiating agents of HL-60 cells. <i>Leukemia Research</i> , 2007, 31, 683-689.	0.4	5
629	HDAC3: taking the SMRT-N-CoR road to repression. <i>Oncogene</i> , 2007, 26, 5439-5449.	2.6	188
630	RAR and RXR modulation in cancer and metabolic disease. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 793-810.	21.5	450
631	Class I HDAC SNP analysis in healthy donors compared to AML patients. <i>Leukemia</i> , 2007, 21, 1587-1590.	3.3	4
632	Role of the Polycomb Repressive Complex 2 in Acute Promyelocytic Leukemia. <i>Cancer Cell</i> , 2007, 11, 513-525.	7.7	228
633	RXR Is an Essential Component of the Oncogenic PML/RARA Complex In Vivo. <i>Cancer Cell</i> , 2007, 12, 23-35.	7.7	101
634	Recruitment of RXR by Homotetrameric RAR β Fusion Proteins Is Essential for Transformation. <i>Cancer Cell</i> , 2007, 12, 36-51.	7.7	93
635	Death Receptors. , 2006, , 219-261.		1
636	Clinical Significance of Histone Deacetylase Inhibitors in Cancer. , 2007, , 335-361.		0
637	Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model. <i>Journal of Neuro-Oncology</i> , 2007, 83, 267-275.	1.4	54
638	Histone deacetylases: target enzymes for cancer therapy. <i>Clinical and Experimental Metastasis</i> , 2008, 25, 183-189.	1.7	145
639	Inhibition of proliferation of human Hela cells by small interference RNA against Pokemon gene. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2008, 20, 5-11.	0.7	1
640	Chemical regulation of epigenetic modifications: Opportunities for new cancer therapy. <i>Medicinal Research Reviews</i> , 2008, 28, 645-687.	5.0	107
641	Nuclear microenvironment in cancer diagnosis and treatment. <i>Journal of Cellular Biochemistry</i> , 2008, 104, 1953-1963.	1.2	7
642	Histone Deacetylase Inhibitors: Mechanisms and Clinical Significance in Cancer: HDAC Inhibitor-Induced Apoptosis. <i>Advances in Experimental Medicine and Biology</i> , 2008, 615, 261-298.	0.8	141
643	Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. <i>EMBO Journal</i> , 2008, 27, 1017-1028.	3.5	238
644	Epigenetic plasticity of chromatin in embryonic and hematopoietic stem/progenitor cells: therapeutic potential of cell reprogramming. <i>Leukemia</i> , 2008, 22, 1503-1518.	3.3	55

#	ARTICLE	IF	CITATIONS
645	Auranofin promotes retinoic acid- or dihydroxyvitamin D ₃ -mediated cell differentiation of promyelocytic leukaemia cells by increasing histone acetylation. <i>British Journal of Pharmacology</i> , 2008, 154, 1196-1205.	2.7	12
646	Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. <i>Histopathology</i> , 2008, 53, 267-277.	1.6	109
647	Retinoblastoma protein and the leukemia-associated PLZF transcription factor interact to repress target gene promoters. <i>Oncogene</i> , 2008, 27, 5260-5266.	2.6	10
648	Dietary Components Impact Histone Modifications and Cancer Risk. <i>Nutrition Reviews</i> , 2007, 65, 88-94.	2.6	80
649	Membrane-anchored growth factors, the epidermal growth factor family: Beyond receptor ligands. <i>Cancer Science</i> , 2008, 99, 214-220.	1.7	195
650	The alpha subunit of Go interacts with promyelocytic leukemia zinc finger protein and modulates its functions. <i>Cellular Signalling</i> , 2008, 20, 884-891.	1.7	14
651	The Transcription Factor PLZF Directs the Effector Program of the NKT Cell Lineage. <i>Immunity</i> , 2008, 29, 391-403.	6.6	637
652	Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression. <i>Biomedicine and Pharmacotherapy</i> , 2008, 62, 85-93.	2.5	35
653	Coiled-coil domain of PML is essential for the aberrant dynamics of PML-RAR α , resulting in sequestration and decreased mobility of SMRT. <i>Biochemical and Biophysical Research Communications</i> , 2008, 365, 258-265.	1.0	9
654	Molecularly Targeted Therapies for Pediatric Acute Myeloid Leukemia. <i>Paediatric Drugs</i> , 2008, 10, 85-92.	1.3	10
655	Design, Synthesis, and Evaluation of Novel Mutual Prodrugs (Hybrid Drugs) of All- <i>trans</i> -Retinoic Acid and Histone Deacetylase Inhibitors with Enhanced Anticancer Activities in Breast and Prostate Cancer Cells in Vitro. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 3895-3904.	2.9	37
656	Topoisomerase II β Negatively Modulates Retinoic Acid Receptor α Function: a Novel Mechanism of Retinoic Acid Resistance. <i>Molecular and Cellular Biology</i> , 2008, 28, 2066-2077.	1.1	59
657	Effect of <i>Trans</i> -2,3-Dimethoxycinnamoyl Azide on Enhancing Antitumor Activity of Romidepsin on Human Bladder Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 1200-1207.	3.2	13
658	Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 9751-9756.	3.3	87
659	Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 740-748.	1.9	47
660	Oncoproteins, heterochromatin silencing and microRNAs: a new link for leukemogenesis. <i>Epigenetics</i> , 2008, 3, 1-4.	1.3	31
661	<i>rosy</i> Function Is Required for Juvenile Hormone Effects in <i>Drosophila melanogaster</i> . <i>Genetics</i> , 2008, 178, 273-281.	1.2	15
662	Lysophosphatidic Acid Protects Cancer Cells from Histone Deacetylase (HDAC) Inhibitor-induced Apoptosis through Activation of HDAC. <i>Journal of Biological Chemistry</i> , 2008, 283, 16818-16829.	1.6	32

#	ARTICLE	IF	CITATIONS
663	MBD3, a Component of the NuRD Complex, Facilitates Chromatin Alteration and Deposition of Epigenetic Marks. <i>Molecular and Cellular Biology</i> , 2008, 28, 5912-5923.	1.1	106
664	Gene transactivation without direct DNA binding defines a novel gain-of-function for PML-RAR \hat{t} . <i>Blood</i> , 2008, 111, 1634-1643.	0.6	27
665	Sp1 up-regulates cAMP-response-element-binding protein expression during retinoic acid-induced mucous differentiation of normal human bronchial epithelial cells. <i>Biochemical Journal</i> , 2008, 410, 49-61.	1.7	11
666	Retinoic acid receptors, hematopoiesis and leukemogenesis. <i>Current Opinion in Hematology</i> , 2008, 15, 346-351.	1.2	63
667	The Proto-Oncogene LRF Is under Post-Transcriptional Control of MiR-20a: Implications for Senescence. <i>PLoS ONE</i> , 2008, 3, e2542.	1.1	79
668	The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation. <i>Genes and Development</i> , 2009, 23, 1195-1206.	2.7	113
669	Expression Levels of Histone Deacetylases Determine the Cell Fate of Hematopoietic Progenitors. <i>Journal of Biological Chemistry</i> , 2009, 284, 30673-30683.	1.6	68
670	A Novel POK Family Transcription Factor, ZBTB5, Represses Transcription of p21CIP1 Gene. <i>Journal of Biological Chemistry</i> , 2009, 284, 19856-19866.	1.6	28
671	Daxx Is a Transcriptional Repressor of CCAAT/Enhancer-binding Protein \hat{t} 2. <i>Journal of Biological Chemistry</i> , 2009, 284, 28783-28794.	1.6	28
672	ZBTB2, a Novel Master Regulator of the p53 Pathway. <i>Journal of Biological Chemistry</i> , 2009, 284, 17935-17946.	1.6	51
673	A Label-free Quantitative Proteomics Strategy to Identify E3 Ubiquitin Ligase Substrates Targeted to Proteasome Degradation. <i>Molecular and Cellular Proteomics</i> , 2009, 8, 1719-1727.	2.5	40
674	Myeloid differentiation continues to reveal the complexity of nuclear receptor signaling. <i>Cell Cycle</i> , 2009, 8, 675-676.	1.3	0
675	Novel targeted drug therapies for the treatment of childhood acute leukemia. <i>Expert Review of Hematology</i> , 2009, 2, 145-158.	1.0	28
676	Targeted therapy in acute myeloid leukaemia: current status and future directions. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 433-455.	1.9	34
677	Therapy-induced <i>PML/RARA</i> Proteolysis and Acute Promyelocytic Leukemia Cure. <i>Clinical Cancer Research</i> , 2009, 15, 6321-6326.	3.2	91
678	Multivalent Binding of the ETO Corepressor to E Proteins Facilitates Dual Repression Controls Targeting Chromatin and the Basal Transcription Machinery. <i>Molecular and Cellular Biology</i> , 2009, 29, 2644-2657.	1.1	25
679	Proto-oncogene FBI-1 Represses Transcription of p21CIP1 by Inhibition of Transcription Activation by p53 and Sp1. <i>Journal of Biological Chemistry</i> , 2009, 284, 12633-12644.	1.6	67
680	Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. <i>Oral Oncology</i> , 2009, 45, 610-614.	0.8	99

#	ARTICLE	IF	CITATIONS
681	A novel Î-lactam-based histone deacetylase inhibitor, KBH-A42, induces cell cycle arrest and apoptosis in colon cancer cells. <i>Biochemical Pharmacology</i> , 2009, 78, 486-494.	2.0	21
682	Curing APL: Differentiation or Destruction?. <i>Cancer Cell</i> , 2009, 15, 7-8.	7.7	38
684	Cancer nucleus: Morphology and beyond. <i>Diagnostic Cytopathology</i> , 2010, 38, 382-390.	0.5	86
685	Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma. <i>International Journal of Hematology</i> , 2009, 89, 45-57.	0.7	27
686	Histone deacetylase 1, 2, 6 and acetylated histone H4 in Bâ€•and Tâ€•cell lymphomas. <i>Histopathology</i> , 2009, 54, 688-698.	1.6	118
687	Response of Retinoic Acidâ€•Resistant KG1 Cells to Combination of Retinoic Acid with Diverse Histone Deacetylase Inhibitors. <i>Annals of the New York Academy of Sciences</i> , 2009, 1171, 321-333.	1.8	17
688	Ethanolâ€•Responsive Genes (<i>Crtam</i>, <i>Zbtb16</i>, and <i>Mobp</i>) Located in the Alcoholâ€•QTL Region of Chromosome 9 Are Associated With Alcohol Preference in Mice. <i>Alcoholism: Clinical and Experimental Research</i> , 2009, 33, 1409-1416.	1.4	13
689	Global histone profiling by LCâ€•FTMS after inhibition and knockdown of deacetylases in human cells. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 3885-3892.	1.2	22
690	The GTPase domain of Galphao contributes to the functional interaction of Galphao with the promyelocytic leukemia zinc finger protein. <i>Cellular and Molecular Biology Letters</i> , 2009, 14, 46-56.	2.7	2
691	Transcription factors, chromatin and cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 164-175.	1.2	40
692	Development of vorinostat: Current applications and future perspectives for cancer therapy. <i>Cancer Letters</i> , 2009, 280, 201-210.	3.2	149
693	Repatterning in amphibian limb regeneration: A model for study of genetic and epigenetic control of organ regeneration. <i>Seminars in Cell and Developmental Biology</i> , 2009, 20, 565-574.	2.3	54
694	Acute Promyelocytic Leukemia: A Paradigm for Differentiation Therapy. <i>Cancer Treatment and Research</i> , 2009, 145, 219-235.	0.2	61
695	Epigenetic Mechanisms in AML â€• A Target for Therapy. <i>Cancer Treatment and Research</i> , 2009, 145, 19-40.	0.2	51
696	Promise and challenges in drug discovery and development of hybrid anticancer drugs. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 1099-1111.	2.5	164
697	Central Nervous System Relapse in Acute Promyelocytic Leukemia: Two Cases and a Systematic Review. <i>Clinical Leukemia</i> , 2009, 3, 58-64.	0.2	1
699	REDD1, a new Ras oncogenic effector. <i>Cell Cycle</i> , 2009, 8, 675-676.	1.3	10
700	Deficient histone acetylation and excessive deacetylase activity as epigenomic marks of prostate cancer cells. <i>International Journal of Oncology</i> , 2009, 35, 1417-22.	1.4	18

#	ARTICLE	IF	CITATIONS
701	Comprehensive genomic screens identify a role for PLZF-RAR $\hat{\pm}$ as a positive regulator of cell proliferation via direct regulation of c-MYC. <i>Blood</i> , 2009, 114, 5499-5511.	0.6	53
702	Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. <i>Blood</i> , 2010, 116, 2324-2331.	0.6	235
703	BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia. <i>Blood</i> , 2010, 116, 4274-4283.	0.6	131
704	Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. <i>Blood</i> , 2010, 116, 406-417.	0.6	121
705	Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 2286-2297.	3.3	16
706	Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting. <i>International Journal of Hematology</i> , 2010, 91, 742-747.	0.7	39
707	Suberoyl bishydroxamic acid inhibits the growth of A549 lung cancer cells via caspase-dependent apoptosis. <i>Molecular and Cellular Biochemistry</i> , 2010, 344, 203-210.	1.4	16
708	Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. <i>Investigational New Drugs</i> , 2010, 28, 3-20.	1.2	123
709	PML-RAR $\hat{\pm}$ /RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. <i>Cancer Cell</i> , 2010, 17, 173-185.	7.7	276
710	Discovery of Novel Transcriptional and Epigenetic Targets in APL by Global ChIP Analyses: Emerging Opportunity and Challenge. <i>Cancer Cell</i> , 2010, 17, 112-114.	7.7	20
711	The molecular signature of oncofusion proteins in acute myeloid leukemia. <i>FEBS Letters</i> , 2010, 584, 2662-2669.	1.3	88
712	Kaiso regulates Znf131-mediated transcriptional activation. <i>Experimental Cell Research</i> , 2010, 316, 1692-1705.	1.2	20
713	Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 116, 195-201.	0.6	95
714	Transcription factor co-repressors in cancer biology: roles and targeting. <i>International Journal of Cancer</i> , 2010, 126, 2511-2519.	2.3	84
715	An HDAC1-binding domain within FATS bridges p21 turnover to radiation-induced tumorigenesis. <i>Oncogene</i> , 2010, 29, 2659-2671.	2.6	17
716	The role of PU.1 and GATA-1 transcription factors during normal and leukemogenic hematopoiesis. <i>Leukemia</i> , 2010, 24, 1249-1257.	3.3	151
717	Leukaemogenesis: more than mutant genes. <i>Nature Reviews Cancer</i> , 2010, 10, 23-36.	12.8	286
718	Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. <i>Nature Reviews Cancer</i> , 2010, 10, 775-783.	12.8	420

#	ARTICLE	IF	CITATIONS
719	Anti-Tumor Effect in Human Lung Cancer by a Combination Treatment of Novel Histone Deacetylase Inhibitors: SL142 or SL325 and Retinoic Acids. <i>PLoS ONE</i> , 2010, 5, e13834.	1.1	25
720	PML-RAR \pm and Dnmt3a1 Cooperate <i>in vivo</i> to Promote Acute Promyelocytic Leukemia. <i>Cancer Research</i> , 2010, 70, 8792-8801.	0.4	24
721	Acute Myelogenous Leukemia. <i>Cancer Treatment and Research</i> , 2010, , .	0.2	1
722	Clostridium difficile Toxin A Decreases Acetylation of Tubulin, Leading to Microtubule Depolymerization through Activation of Histone Deacetylase 6, and This Mediates Acute Inflammation. <i>Journal of Biological Chemistry</i> , 2010, 285, 32888-32896.	1.6	52
723	MicroRNA (miRNA)-mediated Interaction between Leukemia/Lymphoma-related Factor (LRF) and Alternative Splicing Factor/Splicing Factor 2 (ASF/SF2) Affects Mouse Embryonic Fibroblast Senescence and Apoptosis*. <i>Journal of Biological Chemistry</i> , 2010, 285, 39551-39563.	1.6	53
724	Elevated NCOR1 disrupts PPAR α / β signaling in prostate cancer and forms a targetable epigenetic lesion. <i>Carcinogenesis</i> , 2010, 31, 1650-1660.	1.3	56
725	Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. <i>Journal of Experimental Medicine</i> , 2010, 207, 2581-2594.	4.2	58
726	Induction of GNE in Myofibers after Muscle Injury. <i>Pathobiology</i> , 2010, 77, 191-199.	1.9	18
727	Interplay of protein misfolding pathway and unfolded-protein response in acute promyelocytic leukemia. <i>Expert Review of Proteomics</i> , 2010, 7, 591-600.	1.3	8
728	Dynamics of epigenetic modifications in leukemia. <i>Briefings in Functional Genomics</i> , 2011, 10, 18-29.	1.3	19
729	Pokemon reduces Bcl α 2 expression through NF κ Bp65: a possible mechanism of hepatocellular carcinoma. <i>Asian Pacific Journal of Tropical Medicine</i> , 2011, 4, 492-497.	0.4	15
730	Epigenetic Mechanisms in Acute Myeloid Leukemia. , 2011, 67, 197-219.		8
731	Epigenetic Aspects of Chronic Diseases. , 2011, , .		3
732	Epigenetics and Disease. , 2011, , .		5
733	Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2011, 12, 1222-1228.	5.1	168
734	Small interfering RNAs: heralding a new era in gene therapy. , 2011, , .		1
735	The epigenomics revolution in myelodysplasia: a clinico-pathological perspective. <i>Pathology</i> , 2011, 43, 536-546.	0.3	12
736	Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines. <i>Journal of Medical Investigation</i> , 2011, 58, 106-109.	0.2	38

#	ARTICLE	IF	CITATIONS
737	Retinoic acid and tributyrin induce in-vitro radioiodine uptake and inhibition of cell proliferation in a poorly differentiated follicular thyroid carcinoma. <i>Nuclear Medicine Communications</i> , 2011, 32, 605-610.	0.5	17
738	Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2011, 6, 354-366.	0.8	3
739	Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. <i>Blood</i> , 2011, 118, 1600-1609.	0.6	105
740	Revisiting the differentiation paradigm in acute promyelocytic leukemia. <i>Blood</i> , 2011, 117, 5795-5802.	0.6	111
741	Histone deacetylase inhibitor enhances the anti-tumor effect of gemcitabine: A special reference to gene-expression microarray analysis. <i>Oncology Reports</i> , 2011, 26, 1057-62.	1.2	11
742	Towards novel paradigms for cancer therapy. <i>Oncogene</i> , 2011, 30, 1-20.	2.6	112
743	Genome-wide functions of PML-RAR α in acute promyelocytic leukaemia. <i>British Journal of Cancer</i> , 2011, 104, 554-558.	2.9	54
744	Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. <i>Leukemia</i> , 2011, 25, 226-235.	3.3	144
745	Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon- α on pancreatic cancer cells. <i>International Journal of Clinical Oncology</i> , 2011, 16, 671-678.	1.0	26
746	Retinoic acid pathway activity in wilms tumors and characterization of biological responses in vitro. <i>Molecular Cancer</i> , 2011, 10, 136.	7.9	21
748	The deacetylase inhibitor LAQ824 induces notch signalling in haematopoietic progenitor cells. <i>Leukemia Research</i> , 2011, 35, 119-125.	0.4	13
749	Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival. <i>Leukemia Research</i> , 2011, 35, 620-625.	0.4	28
750	Treatment with 5-Azacytidine Accelerates Acute Promyelocytic Leukemia Leukemogenesis in a Transgenic Mouse Model. <i>Genes and Cancer</i> , 2011, 2, 160-165.	0.6	2
751	The Role of HDACs Inhibitors in Childhood and Adolescence Acute Leukemias. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-9.	3.0	24
752	Evaluation of the pharmacokinetics and metabolism of a novel histone deacetylase inhibitor, KBH-A40, in rats. <i>Xenobiotica</i> , 2011, 41, 155-163.	0.5	1
753	KR-POK Interacts with p53 and Represses Its Ability to Activate Transcription of p21WAF1/CDKN1A. <i>Cancer Research</i> , 2012, 72, 1137-1148.	0.4	28
754	Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL. <i>Leukemia</i> , 2012, 26, 1630-1637.	3.3	48
755	Molecular genetics of acute myeloid leukemia. , 0, , 204-238.		2

#	ARTICLE	IF	CITATIONS
756	Retinoids: novel immunomodulators and tumour-suppressive agents?. <i>British Journal of Pharmacology</i> , 2012, 167, 483-492.	2.7	20
757	Valproic acid triggers erythro/megakaryocyte lineage decision through induction of GFI1B and MLLT3 expression. <i>Experimental Hematology</i> , 2012, 40, 1043-1054.e6.	0.2	13
758	Dominant-negative mechanism of leukemogenic PAX5 fusions. <i>Oncogene</i> , 2012, 31, 966-977.	2.6	34
759	Requirement of p38 MAPK for a cell-death pathway triggered by vorinostat in MDA-MB-231 human breast cancer cells. <i>Cancer Letters</i> , 2012, 315, 112-121.	3.2	32
760	Curcumin Analogues with Potent and Selective Anti-proliferative Activity on Acute Promyelocytic Leukemia: Involvement of Accumulated Misfolded Nuclear Receptor Co-repressor (NCoR) Protein as a Basis for Selective Activity. <i>ChemMedChem</i> , 2012, 7, 1567-1579.	1.6	22
761	All-trans retinoic acid in the treatment of pediatric acute promyelocytic leukemia. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1191-1204.	1.1	38
762	The proto-oncoprotein KR-POK represses transcriptional activation of CDKN1A by MIZ-1 through competitive binding. <i>Oncogene</i> , 2012, 31, 1442-1458.	2.6	12
763	DNA methyltransferase inhibitor RG108 and histone deacetylase inhibitors cooperate to enhance NB4 cell differentiation and E-cadherin expression by chromatin remodelling. <i>Cell Biology International</i> , 2012, 36, 1067-1078.	1.4	30
764	An emerging role for retinoid X receptor β in malignant hematopoiesis. <i>Leukemia Research</i> , 2012, 36, 1075-1081.	0.4	13
765	The Role of Bromodomain Proteins in Regulating Gene Expression. <i>Genes</i> , 2012, 3, 320-343.	1.0	119
766	Altered nuclear cofactor switching in retinoic-resistant variants of the PML-RAR β oncoprotein of acute promyelocytic leukemia. <i>Proteins: Structure, Function and Bioinformatics</i> , 2012, 80, 1095-1109.	1.5	6
767	Nuclear Hormone Receptors Enable Macrophages and Dendritic Cells to Sense Their Lipid Environment and Shape Their Immune Response. <i>Physiological Reviews</i> , 2012, 92, 739-789.	13.1	195
768	Cys2His2 zinc finger protein family: Classification, functions, and major members. <i>Biochemistry (Moscow)</i> , 2012, 77, 217-226.	0.7	139
769	Leukemia/lymphoma-related factor regulates oligodendrocyte lineage cell differentiation in developing white matter. <i>Glia</i> , 2012, 60, 1378-1390.	2.5	7
770	Valproic acid: Growth inhibition of head and neck cancer by induction of terminal differentiation and senescence. <i>Head and Neck</i> , 2012, 34, 344-353.	0.9	43
771	Epigenetic changes by zebularine leading to enhanced differentiation of human promyelocytic leukemia NB4 and KG1 cells. <i>Molecular and Cellular Biochemistry</i> , 2012, 359, 245-261.	1.4	23
772	Leukemias, Lymphomas, and Other Related Disorders. , 2013, , 1-44.		2
773	Genetic engineering of Plum pox virus resistance: "HoneySweet" plum from concept to product. <i>Plant Cell, Tissue and Organ Culture</i> , 2013, 115, 1-12.	1.2	109

#	ARTICLE	IF	CITATIONS
774	Quantum polarized ligand docking investigation to understand the significance of protonation states in histone deacetylase inhibitors. <i>Journal of Molecular Graphics and Modelling</i> , 2013, 44, 44-53.	1.3	22
775	Transcriptional corepressors in cancer. <i>Cancer</i> , 2013, 119, 1120-1128.	2.0	10
776	Interaction with RXR is necessary for NPM-RAR-induced myeloid differentiation blockade. <i>Leukemia Research</i> , 2013, 37, 1704-1710.	0.4	5
777	Hydroxamic Acids. , 2013, , .		30
778	Epigenetic distortion to VDR transcriptional regulation in prostate cancer cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013, 136, 258-263.	1.2	12
779	Epigenetic Alterations in Oncogenesis. <i>Advances in Experimental Medicine and Biology</i> , 2013, 754, v-vii.	0.8	10
780	Epigenetic changes: a common theme in acute myelogenous leukemogenesis. <i>Journal of Hematology and Oncology</i> , 2013, 6, 57.	6.9	55
781	The Histone Demethylase PHF8 Governs Retinoic Acid Response in Acute Promyelocytic Leukemia. <i>Cancer Cell</i> , 2013, 23, 376-389.	7.7	76
782	Altered Histone Modifications in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2013, 754, 81-107.	0.8	36
783	Immediate early response genes and cell transformation. , 2013, 137, 64-77.		101
784	Acute Promyelocytic Leukemia. , 2013, , 403-453.		0
785	HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. <i>Cell Death and Disease</i> , 2013, 4, e519-e519.	2.7	150
786	Epigenetic Therapies in MDS and AML. <i>Advances in Experimental Medicine and Biology</i> , 2013, 754, 253-283.	0.8	52
787	The class I-specific HDAC inhibitor MS-275 modulates the differentiation potential of mouse embryonic stem cells. <i>Biology Open</i> , 2013, 2, 1070-1077.	0.6	17
788	Histone deacetylase inhibitors for the treatment of breast cancer: recent trial data. <i>Clinical Investigation</i> , 2013, 3, 557-569.	0.0	3
789	PLZF Regulates Fibroblast Growth Factor Responsiveness and Maintenance of Neural Progenitors. <i>PLoS Biology</i> , 2013, 11, e1001676.	2.6	59
790	RBB, a novel transcription repressor, represses the transcription of HDM2 oncogene. <i>Oncogene</i> , 2013, 32, 3711-3721.	2.6	25
791	Chromatin acetylation at transcription start sites and vitamin D receptor binding regions relates to effects of 1 α ,25-dihydroxyvitamin D3 and histone deacetylase inhibitors on gene expression. <i>Nucleic Acids Research</i> , 2013, 41, 110-124.	6.5	123

#	ARTICLE	IF	CITATIONS
792	Tzfp Represses the Androgen Receptor in Mouse Testis. PLoS ONE, 2013, 8, e62314.	1.1	12
793	Oncogenic Actions of the Nuclear Receptor Corepressor (NCOR1) in a Mouse Model of Thyroid Cancer. PLoS ONE, 2013, 8, e67954.	1.1	20
794	Epigenetic Contributions to the Cancer Transcriptome. , 2014, , 367-380.		0
795	The DNA Binding Property of PML/RARA but Not the Integrity of PML Nuclear Bodies Is Indispensable for Leukemic Transformation. PLoS ONE, 2014, 9, e104906.	1.1	3
796	Transforming the Future of Treatment for Ovarian Cancer. Clinical & Experimental Pharmacology, 2014, 04, .	0.3	0
797	New and emerging HDAC inhibitors for cancer treatment. Journal of Clinical Investigation, 2014, 124, 30-39.	3.9	1,137
798	Anti-Epileptic Drug Targets Ewing Sarcoma. Journal of Pharmaceutical Sciences and Pharmacology, 2014, 1, 87-100.	0.2	7
799	DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance. Chromosoma, 2014, 123, 545-561.	1.0	65
800	Context-Selective Death of Acute Myeloid Leukemia Cells Triggered by the Novel Hybrid Retinoid-HDAC Inhibitor MC2392. Cancer Research, 2014, 74, 2328-2339.	0.4	33
801	Retinoic acid signaling in cancer: The parable of acute promyelocytic leukemia. International Journal of Cancer, 2014, 135, 2262-2272.	2.3	67
802	Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2014, 61, 245-252.	0.8	37
803	Epigenetics in the hematologic malignancies. Haematologica, 2014, 99, 1772-1783.	1.7	60
804	Molecular Targets. Cancer Drug Discovery and Development, 2014, , 1-21.	0.2	0
805	Promyelocytic Leukemia Zinc Finger-Retinoic Acid Receptor $\hat{\pm}$ (PLZF-RAR $\hat{\pm}$), an Oncogenic Transcriptional Repressor of Cyclin-dependent Kinase Inhibitor 1A (p21WAF/CDKN1A) and Tumor Protein p53 (TP53) Genes. Journal of Biological Chemistry, 2014, 289, 18641-18656.	1.6	19
806	Role of Promyelocytic Leukemia Zinc Finger (PLZF) in Cell Proliferation and Cyclin-dependent Kinase Inhibitor 1A (p21WAF/CDKN1A) Gene Repression. Journal of Biological Chemistry, 2014, 289, 18625-18640.	1.6	37
807	Human Kr $\hat{\pm}$ 4ppel-related 3 (HKR3) Is a Novel Transcription Activator of Alternate Reading Frame (ARF) Gene. Journal of Biological Chemistry, 2014, 289, 4018-4031.	1.6	8
808	Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells. Anti-Cancer Drugs, 2014, 25, 938-949.	0.7	30
809	The gene signature in CCAAT-enhancer-binding protein $\hat{\pm}$ dysfunctional acute myeloid leukemia predicts responsiveness to histone deacetylase inhibitors. Haematologica, 2014, 99, 697-705.	1.7	13

#	ARTICLE	IF	CITATIONS
810	The genome-wide molecular signature of transcription factors in leukemia. <i>Experimental Hematology</i> , 2014, 42, 637-650.	0.2	13
811	Analysis of the DNA methylome and transcriptome in granulopoiesis reveals timed changes and dynamic enhancer methylation. <i>Blood</i> , 2014, 123, e79-e89.	0.6	72
812	Understanding the molecular pathogenesis of acute promyelocytic leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 3-9.	0.7	66
813	Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells. <i>Biomedicine and Pharmacotherapy</i> , 2014, 68, 327-334.	2.5	63
814	Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 673-691.	21.5	1,277
815	Synthesis and Evaluation of Bisbenzylidenedioxotetrahydrothiopyranones as Activators of Endoplasmic Reticulum (ER) Stress Signaling Pathways and Apoptotic Cell Death in Acute Promyelocytic Leukemic Cells. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 5904-5918.	2.9	26
816	Acute promyelocytic leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 1.	0.7	2
817	Triple A therapy: The molecular underpinnings of the unique sensitivity of leukemic promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 19-31.	0.7	11
818	Molecular Mechanisms of the Antileukemia Activities of Retinoid and Arsenic. <i>Journal of Pharmacological Sciences</i> , 2014, 126, 179-185.	1.1	16
819	TBLR1 fuses to retinoid acid receptor β in a variant t(3;17)(q26;q21) translocation of acute promyelocytic leukemia. <i>Blood</i> , 2014, 124, 936-945.	0.6	51
820	Oncolytic Viruses and Histone Deacetylase Inhibitors. , 2014, , 437-466.		0
821	Enhancement of differentiation induction and upregulation of CCAAT/enhancer-binding proteins and PU.1 in NB4 cells treated with combination of ATRA and valproic acid. <i>International Journal of Oncology</i> , 2014, 44, 865-873.	1.4	20
822	Epigenetic alterations in acute myeloid leukemias. <i>FEBS Journal</i> , 2015, 282, 1786-1800.	2.2	36
823	Belinostat, a potent HDAC inhibitor, exerts antileukaemic effect in human acute promyelocytic leukaemia cells via chromatin remodelling. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 1742-1755.	1.6	24
824	Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer. <i>Journal of Internal Medicine</i> , 2015, 278, 627-642.	2.7	31
825	Inhibition of MTA1 by ER β contributes to protection hepatocellular carcinoma from tumor proliferation and metastasis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 128.	3.5	34
826	Post transcriptional control of the epigenetic stem cell regulator PLZF by sirtuin and HDAC deacetylases. <i>Epigenetics and Chromatin</i> , 2015, 8, 38.	1.8	11
827	A novel zinc finger gene, <i>ZNF465</i> , is inappropriately expressed in acute myeloid leukaemia cells. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 288-302.	1.5	1

#	ARTICLE	IF	CITATIONS
829	Perspective on Therapeutic Strategies of Leukemia Treatment – Focus on Arsenic Compounds. , 2015, , .		0
830	Regulation of the C/EBP β signaling pathway in acute myeloid leukemia (Review). <i>Oncology Reports</i> , 2015, 33, 2099-2106.	1.2	12
831	Acute Promyelocytic Leukaemia: From a Specific Translocation to Cure by Targeted Therapies. , 2015, , 251-273.		0
832	Gene Networks, Epigenetics and the Control of Female Puberty. <i>Research and Perspectives in Endocrine Interactions</i> , 2015, , 97-119.	0.2	1
833	Retinoic acid receptors: From molecular mechanisms to cancer therapy. <i>Molecular Aspects of Medicine</i> , 2015, 41, 1-115.	2.7	284
834	Chromatin Dynamics during Differentiation of Myeloid Cells. <i>Journal of Molecular Biology</i> , 2015, 427, 670-687.	2.0	12
835	Histone deacetylase inhibitors in hematological malignancies and solid tumors. <i>Archives of Pharmacal Research</i> , 2015, 38, 933-949.	2.7	106
836	Epigenetics in acute promyelocytic leukaemia pathogenesis and treatment response: A TRAnSition to targeted therapies. <i>British Journal of Cancer</i> , 2015, 112, 413-418.	2.9	21
837	Transcription and methylation analysis of preleukemic promyelocytes indicate a dual role for PML/RARA in leukemia initiation. <i>Haematologica</i> , 2015, 100, 1064-75.	1.7	14
838	The acetyltransferase HAT1 moderates the NF- κ B response by regulating the transcription factor PLZF. <i>Nature Communications</i> , 2015, 6, 6795.	5.8	62
839	TRPM2 Mediates Histone Deacetylase Inhibition-Induced Apoptosis in Bladder Cancer Cells. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2015, 30, 87-93.	0.7	17
840	Antagonism between granulocytic maturation and deacetylase inhibitor-induced apoptosis in acute promyelocytic leukaemia cells. <i>British Journal of Cancer</i> , 2015, 112, 329-337.	2.9	8
841	Targeting Transcription Factors in Cancer. <i>Trends in Cancer</i> , 2015, 1, 53-65.	3.8	247
842	Short linear motif acquisition, exon formation and alternative splicing determine a pathway to diversity for NCoR-family co-repressors. <i>Open Biology</i> , 2015, 5, 150063.	1.5	8
844	Different Patterns of Acetylation and Dimethylation of Histone H3 between Young and Aged Cases with Chronic Tonsillitis: Influences of Inflammation and Aging. <i>Journal of Nippon Medical School</i> , 2016, 83, 54-61.	0.3	2
845	The Involvement of Epigenetic Mechanisms in HPV-Induced Cervical Cancer. , 0, , .		2
846	Epigenetics in Brain Tumors: HDACs Take Center Stage. <i>Current Neuropharmacology</i> , 2016, 14, 48-54.	1.4	21
847	How do tumor cells respond to HDAC inhibition?. <i>FEBS Journal</i> , 2016, 283, 4032-4046.	2.2	97

#	ARTICLE	IF	CITATIONS
848	PLZF mutation alters mouse hematopoietic stem cell function and cell cycle progression. <i>Blood</i> , 2016, 127, 1881-1885.	0.6	29
849	PML regulates neuroprotective innate immunity and neuroblast commitment in a hypoxic-ischemic encephalopathy model. <i>Cell Death and Disease</i> , 2016, 7, e2320-e2320.	2.7	9
850	Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity. <i>BMC Cancer</i> , 2016, 16, 667.	1.1	16
852	Sensitive method for the determination of rocilinostat in small volume mouse plasma by LC-MS/MS and its application to a pharmacokinetic study in mice. <i>Biomedical Chromatography</i> , 2016, 30, 1138-1144.	0.8	2
853	Regulation of hematopoietic development by ZBTB transcription factors. <i>International Journal of Hematology</i> , 2016, 104, 310-323.	0.7	67
854	Role of ND10 nuclear bodies in the chromatin repression of HSV-1. <i>Virology Journal</i> , 2016, 13, 62.	1.4	25
855	Emerging Roles of Epigenetic Regulator Sin3 in Cancer. <i>Advances in Cancer Research</i> , 2016, 130, 113-135.	1.9	44
856	Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 307-317.	1.9	45
857	NPM and BRG1 Mediate Transcriptional Resistance to Retinoic Acid in Acute Promyelocytic Leukemia. <i>Cell Reports</i> , 2016, 14, 2938-2949.	2.9	13
858	An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 687-696.	1.9	21
859	PML is required for telomere stability in non-neoplastic human cells. <i>Oncogene</i> , 2016, 35, 1811-1821.	2.6	23
860	The oncofusion protein FUS-ERG targets key hematopoietic regulators and modulates the all-trans retinoic acid signaling pathway in t(16;21) acute myeloid leukemia. <i>Oncogene</i> , 2016, 35, 1965-1976.	2.6	39
861	Single-Molecule Investigations on Histone H2A-H2B Dynamics in the Nucleosome. <i>Biochemistry</i> , 2017, 56, 977-985.	1.2	25
862	Chemotherapy for Leukemia. , 2017, , .		2
863	All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells. <i>Cell Death and Disease</i> , 2017, 8, e2782-e2782.	2.7	15
864	Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation. <i>Experimental Hematology</i> , 2017, 52, 12-23.	0.2	36
866	Effect of ATRA and ATO on the expression of tissue factor in NB4 acute promyelocytic leukemia cells and regulatory function of the inflammatory cytokines TNF and IL-1 β . <i>Annals of Hematology</i> , 2017, 96, 905-917.	0.8	9
867	Bioinformatic approaches to interrogating vitamin D receptor signaling. <i>Molecular and Cellular Endocrinology</i> , 2017, 453, 3-13.	1.6	11

#	ARTICLE	IF	CITATIONS
868	Validation of an LC-MS/MS method for simultaneous detection of four HDAC inhibitors – belinostat, panobinostat, rocilinostat and vorinostat in mouse plasma and its application to a mouse pharmacokinetic study. <i>Biomedical Chromatography</i> , 2017, 31, e3912.	0.8	6
869	Vitamin D Receptor Signaling and Cancer. <i>Endocrinology and Metabolism Clinics of North America</i> , 2017, 46, 1009-1038.	1.2	52
870	Animacroxam, a Novel Dual-Mode Compound Targeting Histone Deacetylases and Cytoskeletal Integrity of Testicular Germ Cell Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2364-2374.	1.9	13
871	Synthesis, characterization, and evaluation of Cd[L-proline] ₂ , a novel histone deacetylase inhibitor that induces epigenetic modification of histone deacetylase isoforms in A549 cells. <i>Investigational New Drugs</i> , 2017, 35, 691-705.	1.2	9
872	Histone Deacetylase Inhibition Restores Expression of Hypoxia-Inducible Protein NDRG1 in Pancreatic Cancer. <i>Pancreas</i> , 2018, 47, 200-207.	0.5	19
873	Molecular Genetics of APL , 2018, , 41-53.		1
875	Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4). <i>Annals of Hematology</i> , 2018, 97, 83-93.	0.8	23
876	Low HOX gene expression in PML-RAR α -positive leukemia results from suppressed histone demethylation. <i>Epigenetics</i> , 2018, 13, 73-84.	1.3	16
877	Differentiation therapy revisited. <i>Nature Reviews Cancer</i> , 2018, 18, 117-127.	12.8	320
878	Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia. <i>Oncotarget</i> , 2018, 9, 25647-25660.	0.8	13
879	A Novel Therapeutic Approach in Acute Promyelocytic Leukemia with All-trans retinoic Acid and Cyclin-dependent Kinase Inhibitors. <i>Clinical Cancer Drugs</i> , 2018, 5, 50-59.	0.3	0
880	Alteration of the Retinoid Acid-CBP Signaling Pathway in Neural Crest Induction Contributes to Enteric Nervous System Disorder. <i>Frontiers in Pediatrics</i> , 2018, 6, 382.	0.9	8
881	Sin3A recruits Tet1 to the PAH1 domain via a highly conserved Sin3-Interaction Domain. <i>Scientific Reports</i> , 2018, 8, 14689.	1.6	27
882	The Emerging Role of Epigenetics. <i>Translational Bioinformatics</i> , 2018, , 65-101.	0.0	1
884	Acute Promyelocytic Leukemia. , 2018, , .		2
885	Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2018, 8, 41.	1.3	56
886	C/EBP β RS derived from a neutrophil-specific granule deficiency patient interacts with HDAC1 and its dysfunction is restored by trichostatin A. <i>Biochemical and Biophysical Research Communications</i> , 2019, 516, 293-299.	1.0	6
887	Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration. <i>Cell Reports</i> , 2019, 29, 2338-2354.e7.	2.9	74

#	ARTICLE	IF	CITATIONS
888	PML ϵ -RAR α induces all-trans retinoic acid-dependent transcriptional activation through interaction with MED1. <i>Transcription</i> , 2019, 10, 147-156.	1.7	0
889	Acute promyelocytic leukemia and variant fusion proteins: PLZF-RAR α fusion protein at a glance. <i>Seminars in Oncology</i> , 2019, 46, 133-144.	0.8	16
890	Advances in precision epigenetic treatment for acute promyelocytic leukemia.. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 163-178.	0.4	1
891	HDAC1-mediated repression of the retinoic acid-responsive gene <i>rippy3</i> promotes second heart field development. <i>PLoS Genetics</i> , 2019, 15, e1008165.	1.5	16
892	The regulatory elements of PLZF gene are not conserved as revealed by molecular cloning and functional characterization of PLZF gene promoter of <i>Clarias batrachus</i> . <i>Gene Reports</i> , 2019, 16, 100402.	0.4	0
893	RNF8 is responsible for ATRA resistance in variant acute promyelocytic leukemia with GTF2I/RARA fusion, and inhibition of the ubiquitin ϵ proteasome pathway contributes to the reversion of ATRA resistance. <i>Cancer Cell International</i> , 2019, 19, 84.	1.8	6
895	Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1291.	1.8	47
896	Targeting chromatin complexes in fusion protein-driven malignancies. <i>Nature Reviews Cancer</i> , 2019, 19, 255-269.	12.8	55
897	PLZF limits enhancer activity during hematopoietic progenitor aging. <i>Nucleic Acids Research</i> , 2019, 47, 4509-4520.	6.5	15
898	How Protein Binding Sensitizes the Nucleosome to Histone H3K56 Acetylation. <i>ACS Chemical Biology</i> , 2019, 14, 506-515.	1.6	15
899	Design, synthesis and evaluation of belinostat analogs as histone deacetylase inhibitors. <i>Future Medicinal Chemistry</i> , 2019, 11, 2765-2778.	1.1	3
900	CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia. <i>Anti-Cancer Drugs</i> , 2020, 31, 158-168.	0.7	6
901	Recent insights into Histone Acetyltransferase-1: biological function and involvement in pathogenesis. <i>Epigenetics</i> , 2021, 16, 838-850.	1.3	21
902	Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. <i>Cells</i> , 2020, 9, 2423.	1.8	12
903	Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability. <i>Genes</i> , 2020, 11, 556.	1.0	170
904	Effect of epigenetic modulation on cancer sphere. <i>Journal of Medical Investigation</i> , 2020, 67, 70-74.	0.2	0
905	EGFR ϵ downregulated H2AZK4/7AC though the PI3K/AKT ϵ HDAC2 axis to regulate cell cycle progression. <i>Clinical and Translational Medicine</i> , 2020, 9, 10.	1.7	15
906	PML Nuclear Body Biogenesis, Carcinogenesis, and Targeted Therapy. <i>Trends in Cancer</i> , 2020, 6, 889-906.	3.8	33

#	ARTICLE	IF	CITATIONS
907	Risk of carcinogenesis in the biliary epithelium of children with congenital biliary dilatation through epigenetic and genetic regulation. <i>Surgery Today</i> , 2022, 52, 215-223.	0.7	5
908	KDM5A suppresses PML-RAR α target gene expression and APL differentiation through repressing H3K4me2. <i>Blood Advances</i> , 2021, 5, 3241-3253.	2.5	16
909	Translocations, fusion genes, and acute leukemia. <i>Journal of Cellular Biochemistry</i> , 1998, 72, 264-276.	1.2	1
910	Targeted histone deacetylase inhibition for cancer prevention and therapy. , 2005, 63, 147-191.		7
911	Current approaches to acute promyelocytic leukemia. , 1999, 99, 125-153.		4
912	The Molecular Cancer Biology of the VDR. , 2011, , 25-52.		6
913	The Impact of Biology on the Treatment of Secondary AML. <i>Cancer Treatment and Research</i> , 2001, 108, 231-255.	0.2	10
914	Genetic Markers in Sporadic Tumors. , 2004, , 73-150.		1
915	Cancer Drugs and Cancer Drug Development for the New Millennium. , 2000, , 91-109.		3
916	Retinoic acid receptors in normal and neoplastic haematopoietic cells. , 2000, , 129-139.		1
917	Monoclonal Antibody Therapy of APL. , 2007, 313, 205-219.		3
918	The Design of Selective and Non-selective Combination Therapy for Acute Promyelocytic Leukemia. , 2007, 313, 245-269.		10
919	The PLZF Gene of t(11;17)-Associated APL. , 2007, 313, 31-48.		24
920	The Theory of APL Revisited. , 2007, 313, 85-100.		46
921	Arsenic Trioxide and Acute Promyelocytic Leukemia: Clinical and Biological. <i>Current Topics in Microbiology and Immunology</i> , 2007, 313, 129-144.	0.7	25
922	Hydroxamic Acids as Histone Deacetylase Inhibitors. , 2013, , 99-151.		1
923	Antiproliferative Signalling by 1, 25(OH)2D3 in Prostate and Breast Cancer Is Suppressed by a Mechanism Involving Histone Deacetylation. <i>Recent Results in Cancer Research</i> , 2003, 164, 83-98.	1.8	39
924	The Retinoids: Cancer Therapy and Prevention Mechanisms. <i>Handbook of Experimental Pharmacology</i> , 1999, , 301-322.	0.9	19

#	ARTICLE	IF	CITATIONS
925	Retinoic Acid in Myeloid Differentiation and Acute Promyelocytic Leukemia (APL). <i>Hamatologie Und Bluttransfusion</i> , 2003, , 52-61.	0.0	2
926	Corepressors and Nuclear Hormone Receptor Function. <i>Current Topics in Microbiology and Immunology</i> , 2001, 254, 101-116.	0.7	72
927	Regulation of SMRT and N-CoR Corepressor Function. <i>Current Topics in Microbiology and Immunology</i> , 2001, 254, 117-136.	0.7	41
928	Role of Nuclear Receptor Corepressors in Leukemogenesis. <i>Current Topics in Microbiology and Immunology</i> , 2001, 254, 165-185.	0.7	11
929	Deregulated expression of promyelocytic leukemia zinc finger protein in B-cell chronic lymphocytic leukemias does not affect cyclin A expression. <i>The Hematology Journal</i> , 2000, 1, 15-27.	2.0	17
930	Down-stream regions of the POZ-domain influence the interaction of the t(11;17)-associated PLZF/RAR α fusion protein with the histone-deacetylase recruiting co-repressor complex. <i>The Hematology Journal</i> , 2001, 2, 385-392.	2.0	6
931	Identification of the t(15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML/RAR α rearrangement in newly diagnosed AML. <i>British Journal of Haematology</i> , 1999, 105, 198-207.	1.2	14
932	Retinoids in chemoprevention and differentiation therapy. <i>Carcinogenesis</i> , 2000, 21, 1271-1279.	1.3	57
933	The N-terminal BTB/POZ Domain and C-Terminal Sequences Are Essential for Tramtrack69 to Specify Cell Fate in the Developing Drosophila Eye. <i>Genetics</i> , 2000, 156, 195-203.	1.2	47
934	The biology and treatment of acute progranulocytic leukemia. <i>Current Opinion in Oncology</i> , 1999, 11, 9.	1.1	17
935	Thyroid hormone receptor coactivators and corepressors. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 1999, 6, 287.	0.6	2
936	Biology and treatment of acute progranulocytic leukemia. <i>Current Opinion in Hematology</i> , 1999, 6, 236.	1.2	18
937	Vitamin A and regulation of gene expression. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 1998, 1, 341-346.	1.3	25
938	BCoR, a novel corepressor involved in BCL-6 repression. <i>Genes and Development</i> , 2000, 14, 1810-1823.	2.7	383
939	A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. <i>Genes and Development</i> , 2000, 14, 1048-1057.	2.7	412
940	Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. <i>Histopathology</i> , 2008, 53, ???-???	1.6	49
941	Pan-Cancer Analyses of the Nuclear Receptor Superfamily. <i>Nuclear Receptor Research</i> , 2015, 2, .	2.5	40
942	Trichostatin A Up-Regulates Human Papillomavirus Type 11 Upstream Regulatory Region-E6 Promoter Activity in Undifferentiated Primary Human Keratinocytes. <i>Journal of Virology</i> , 1999, 73, 5026-5033.	1.5	35

#	ARTICLE	IF	CITATIONS
944	Thyroid Hormone Receptors, Coregulators, and Disease. , 2008, , 243-280.		7
945	Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. <i>Journal of Clinical Investigation</i> , 2001, 108, 1321-1330.	3.9	100
946	Targeting aberrant transcriptional repression in leukemia: a therapeutic reality?. <i>Journal of Clinical Investigation</i> , 2001, 108, 1277-1278.	3.9	5
947	Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. <i>Journal of Clinical Investigation</i> , 2001, 108, 1321-1330.	3.9	237
948	CaMKII regulates retinoic acid receptor transcriptional activity and the differentiation of myeloid leukemia cells. <i>Journal of Clinical Investigation</i> , 2007, 117, 1412-1421.	3.9	36
949	PML-RARA requires DNA methyltransferase 3A to initiate acute promyelocytic leukemia. <i>Journal of Clinical Investigation</i> , 2015, 126, 85-98.	3.9	36
950	Physical Interaction Between Retinoic Acid Receptor and Sp1: Mechanism for Induction of Urokinase by Retinoic Acid. <i>Blood</i> , 1999, 93, 4264-4276.	0.6	4
951	Constitutive Degradation of PML/RAR α Through the Proteasome Pathway Mediates Retinoic Acid Resistance. <i>Blood</i> , 1999, 93, 1477-1481.	0.6	8
952	1,25-Dihydroxyvitamin D3 Induces Differentiation of a Retinoic Acid α -Resistant Acute Promyelocytic Leukemia Cell Line (UF-1) Associated With Expression of p21WAF1/CIP1 and p27KIP1. <i>Blood</i> , 1999, 93, 2225-2233.	0.6	5
953	Chromatin Remodeling and Leukemia: New Therapeutic Paradigms. <i>Blood</i> , 1999, 94, 417-428.	0.6	42
954	Overexpression of Wild-Type Retinoic Acid Receptor α (RAR α) Recapitulates Retinoic Acid-Sensitive Transformation of Primary Myeloid Progenitors by Acute Promyelocytic Leukemia RAR α -Fusion Genes. <i>Blood</i> , 1999, 94, 793-802.	0.6	11
955	The t(5;17) acute promyelocytic leukemia fusion protein NPM-RAR interacts with co-repressor and co-activator proteins and exhibits both positive and negative transcriptional properties. <i>Blood</i> , 2000, 95, 2683-2690.	0.6	3
956	Differentiation-independent retinoid induction of folate receptor type β 2, a potential tumor target in myeloid leukemia. <i>Blood</i> , 2000, 96, 3529-3536.	0.6	3
957	AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein. <i>Blood</i> , 2000, 96, 3939-3947.	0.6	9
958	Gene expression networks underlying retinoic acid α -induced differentiation of acute promyelocytic leukemia cells. <i>Blood</i> , 2000, 96, 1496-1504.	0.6	12
959	PML/RAR α fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype. <i>Blood</i> , 2000, 96, 1531-1537.	0.6	6
960	Ligand-inducible interaction of the DRIP/TRAP coactivator complex with retinoid receptors in retinoic acid α -sensitive and α -resistant acute promyelocytic leukemia cells. <i>Blood</i> , 2000, 96, 2233-2239.	0.6	1
961	Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia α -associated TEL-AML1 oncoprotein. <i>Blood</i> , 2000, 96, 2557-2561.	0.6	21

#	ARTICLE	IF	CITATIONS
962	Altered ligand binding and transcriptional regulation by mutations in the PML/RAR α ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia. <i>Blood</i> , 2000, 96, 3200-3208.	0.6	3
963	Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. <i>Blood</i> , 2002, 99, 1014-1022.	0.6	4
965	The <i>bric à brac</i> locus consists of two paralogous genes encoding BTB/POZ domain proteins and acts as a homeotic and morphogenetic regulator of imaginal development in <i>Drosophila</i> . <i>Development (Cambridge)</i> , 2002, 129, 2419-2433.	1.2	108
966	The p120 catenin family: Complex roles in adhesion, signaling and cancer. <i>Journal of Cell Science</i> , 2000, 113, 1319-1334.	1.2	388
967	Characterisation of Genome-Wide PLZF/RARA Target Genes. <i>PLoS ONE</i> , 2011, 6, e24176.	1.1	22
968	The Recognition of N-Glycans by the Lectin ArtinM Mediates Cell Death of a Human Myeloid Leukemia Cell Line. <i>PLoS ONE</i> , 2011, 6, e27892.	1.1	27
969	Targeting of Histone Deacetylases to Reactivate Tumour Suppressor Genes and Its Therapeutic Potential in a Human Cervical Cancer Xenograft Model. <i>PLoS ONE</i> , 2013, 8, e80657.	1.1	33
970	The Bromodomain Inhibitor JQ1 Enhances the Responses to All-trans Retinoic Acid in HL-60 and MV4-11 Leukemia Cells. <i>International Journal of Stem Cells</i> , 2018, 11, 131-140.	0.8	13
971	Histone Deacetylase Inhibitors in Tumor Immunotherapy. <i>Current Medicinal Chemistry</i> , 2019, 26, 2990-3008.	1.2	32
972	Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2007, 2, 119-134.	0.8	51
973	Effect of DNA Methyltransferase in Comparison to and in Combination with Histone Deacetylase Inhibitors on Hepatocellular Carcinoma HepG2 Cell Line. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 1119-1125.	0.5	7
974	Targeting of leukemia-initiating cells in acute promyelocytic leukemia. <i>Stem Cell Investigation</i> , 2015, 2, 8.	1.3	16
975	Validation of a RP-HPLC Method for the Quantitation of Vorinostat in Rat Plasma and its Application to a Pharmacokinetic Study. <i>Pharmaceutica Analytica Acta</i> , 2015, 06, .	0.2	3
976	Acute Promyelocytic Leukemia: A Model Disease for Targeted Cancer Therapy. , 0, , .		1
977	Histone Deacetylases and their Inhibitors as Potential Therapeutic Drugs for cholangiocarcinoma - Cell Line findings. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 2503-2508.	0.5	25
978	Applications of developmental biology to medicine and animal agriculture. , 2000, 54, 213-256.		0
980	Molecular Genetics of Acute Promyelocytic Leukemia: A Rationale for "Transcription Therapy" for Cancer. , 2000, , 123-132.		0
981	Retinoid Receptors. , 2001, , 245-295.		1

#	ARTICLE	IF	CITATIONS
982	Chromosomes and Cancer: Activation of Oncogenes. , 2001, , 405-414.		0
983	Coactivators and Corepressors. , 2001, , 389-408.		0
984	Vitamin A and Gene Expression. Modern Nutrition, 2001, , 283-319.	0.1	0
987	Molecular basis of Acute Myelogenous Leukemia. Revista Brasileira De Hematologia E Hemoterapia, 2002, 24, .	0.7	0
988	Akute myeloische Leukämien. , 2003, , 312-350.		0
989	New Developmental Agents and Directions in the Treatment of Acute Myelogenous Leukemia. Hamatologie Und Bluttransfusion, 2003, , 153-160.	0.0	0
990	Modulating Transcription with Artificial Regulators. Handbook of Experimental Pharmacology, 2004, , 535-571.	0.9	0
991	The Retinoids and Cancer Chemoprevention. , 2004, , 277-288.		4
992	Akute myeloische Leukämie. , 2004, , 1847-1915.		0
993	Role of Histone Acetylation in Hematological Malignancies. The Showa University Journal of Medical Sciences, 2004, 16, 1-16.	0.1	0
994	Molecular Pathology of Hematological Malignancies. , 2004, , 239-277.		0
995	Molecular Targets. , 2004, , 1-27.		1
996	The Actions of the Vitamin D Receptor in Health and Malignancy; Polymorphic Associations and Gene Regulatory Actions. , 2006, , 129-175.		0
997	APL: A Classic Tale of Bench to Bedside. , 2007, , 193-228.		1
998	Differentiation Therapy in AML. , 2007, , 293-312.		0
999	Aberrant Transcription Factors in AML. , 2007, , 27-42.		0
1000	Modulating Gene Expression as a Therapeutic Approach in the Treatment of AML. , 2007, , 275-291.		0
1001	BIOLOGY AND EPIDEMIOLOGY OF LUNG CANCER. , 2008, , 708-728.		2

#	ARTICLE	IF	CITATIONS
1002	Histone Deacetylase Inhibitors in Multiple Myeloma. , 2008, , 379-392.		0
1003	Targeted Approaches to Drug Development. , 2009, , 57-98.		3
1005	Promising Targeted Agents. Pediatric Oncology, 2011, , 193-214.	0.5	0
1006	Molecular Therapies. , 2011, , 257-275.		0
1007	Dietary Components, Epigenetics, and Cancer. , 2010, , 77-108.		0
1008	Clinical Trials of Epigenetic Modifiers in the Treatment of Myelodysplastic Syndrome. , 2011, , 217-229.		0
1010	Use of Congenic Mouse Strains for Gene Identification in Type 1 Diabetes. , 0, , .		0
1012	Novel Targeted Therapeutics for Acute Myeloid Leukemia. , 2012, , 315-348.		0
1013	Vitamin D Receptor. Oxidative Stress and Disease, 2012, , 37-64.	0.3	0
1014	Modification of Histone Protein in the Tissue of Laryngeal Cancer. Nihon Ika Daigaku Igakkai Zasshi, 2014, 10, 132-133.	0.0	1
1015	Target acquisition and acute promyelocytic leukemia. Journal of Clinical Investigation, 1999, 103, 1367-1368.	3.9	1
1018	Dosing “When Less is More. RSC Drug Discovery Series, 2015, , 249-266.	0.2	0
1019	Acute Promyelocytic Leukaemia: Epigenetic Function of the PML-RAR α Oncogene. , 2016, , 71-98.		0
1020	Retinoic Acid, All-trans Retinoic Acid (ATRA), and Tamibarotene. , 2017, , 183-211.		2
1022	PML nuclear body biogenesis and oligomerization-driven leukemogenesis. Blood Science, 2020, 2, 7-10.	0.4	1
1023	Acute Myeloid Leukemias. , 2006, , 767-775.		0
1024	Targeting APL Fusion Proteins by Peptide Interference. , 2007, 313, 221-243.		2
1025	Diagnosis and Classification of the Acute Myeloid Leukemias (with Discussion of the Role of the) Tj ETQq1 1 0.784314 rgBT /Overlock		1

#	ARTICLE	IF	CITATIONS
1026	Clinical Presentation, Diagnosis, and Classification of Acute Myeloid Leukemia. Hematologic Malignancies, 2021, , 11-55.	0.2	0
1028	Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway. Genes and Development, 2000, 14, 45-54.	2.7	118
1029	Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Genes and Development, 2000, 14, 55-66.	2.7	154
1030	A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes and Development, 2000, 14, 1048-57.	2.7	348
1031	BCoR, a novel corepressor involved in BCL-6 repression. Genes and Development, 2000, 14, 1810-23.	2.7	331
1032	Cloning and characterization of a novel human histone deacetylase, HDAC8. Biochemical Journal, 2000, 350 Pt 1, 199-205.	1.7	52
1033	DNA recognition by the aberrant retinoic acid receptors implicated in human acute promyelocytic leukemia. Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research, 2001, 12, 85-98.	0.8	14
1035	Nuclear receptor corepressor complexes in cancer: mechanism, function and regulation. American Journal of Clinical and Experimental Urology, 2014, 2, 169-87.	0.4	38
1036	Histone acetyltransferase inhibitor C646 reverses epithelial to mesenchymal transition of human peritoneal mesothelial cells via blocking TGF- β 1/Smad3 signaling pathway in vitro. International Journal of Clinical and Experimental Pathology, 2015, 8, 2746-54.	0.5	20
1037	An updated account on molecular heterogeneity of acute leukemia. American Journal of Blood Research, 2021, 11, 22-43.	0.6	1
1038	Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Genes and Development, 2000, 14, 55-66.	2.7	360
1039	Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway. Genes and Development, 2000, 14, 45-54.	2.7	281
1040	All-Trans-Retinoic Acid Combined With Valproic Acid Can Promote Differentiation in Myeloid Leukemia Cells by an Autophagy Dependent Mechanism. Frontiers in Oncology, 2022, 12, 848517.	1.3	3
1041	Epigenomic alterations in cancer: mechanisms and therapeutic potential. Clinical Science, 2022, 136, 473-492.	1.8	4
1042	Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation. Blood Cancer Journal, 2021, 11, 194.	2.8	5
1043	Modular signaling in hematopoietic malignancies. , 0, , 443-456.		0
1046	Histone modification enzymes: novel targets for cancer drugs. Expert Opinion on Emerging Drugs, 2004, 9, 135-54.	1.0	29
1047	Leukemias, Lymphomas, and Plasma Cell Disorders. , 2023, , 237-300.		0

#	ARTICLE	IF	CITATIONS
1048	CBP and p300: versatile coregulators with important roles in hematopoietic gene expression. <i>Journal of Leukocyte Biology</i> , 2002, 71, 545-556.	1.5	53
1049	Genomic Insights into Non-steroidal Nuclear Receptors in Prostate and Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 227-239.	0.8	2
1050	Co-encapsulation of retinoic acid, curcumin and resveratrol by spray-drying of alginic acid sodium-based emulsions and ethyl cellulose-based solutions: Impact on the co-delivery profiles. <i>International Journal of Biological Macromolecules</i> , 2023, 224, 1217-1227.	3.6	6
1051	Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13657.	1.8	2
1052	Mouse promyelocytic leukemia zinc finger protein (PLZF) regulates hepatic lipid and glucose homeostasis dependent on SIRT1. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
1053	Multimodal approach to characterize the tetrameric form of human PML-RBCC domain and ATO-mediated conformational changes. <i>International Journal of Biological Macromolecules</i> , 2022, 223, 468-478.	3.6	1
1056	Proteomics-based trapping with single or multiple inactive mutants reproducibly profiles histone deacetylase 1 substrates. <i>Journal of Proteomics</i> , 2023, 274, 104807.	1.2	1
1058	Multi-omics and machine learning reveal context-specific gene regulatory activities of PML::RARA in acute promyelocytic leukemia. <i>Nature Communications</i> , 2023, 14, .	5.8	4